

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

20-541/S-006

ADMINISTRATIVE DOCUMENTS

ARIMIDEX™ (anastrozole)

PATENT INFORMATION ON ANY PATENT WHICH CLAIMS THE DRUG

For further information regarding this section, please contact:

Laura E. García-Davenport, M.S.
Senior Regulatory Project Manager
(302) 886-7533
Zeneca Pharmaceuticals
A Business Unit of Zeneca Inc.
1800 Concord Pike
PO Box 15437
Wilmington, DE 19850-5437

ARIMIDEX is a trademark, the property of Zeneca Limited.

Zeneca Pharmaceuticals,
A Business Unit of Zeneca Inc.
Drug Regulatory Affairs Department
Wilmington, DE 19850-5437


ARIMDEX® (anastrozole)
NDA 20-541

Pursuant to Section 505 of the Federal Food, Drug and Cosmetic Act, the attached information following below is made of record.

- A. PATENT INFORMATION ON ANY PATENT WHICH CLAIMS THE DRUG OR A METHOD OF USING THE DRUG

CERTIFICATION

Pursuant to 21 CFR section 314.53(d)(2)(ii), Zeneca Ltd., through its Agent Zeneca Pharmaceuticals, a Business Unit of Zeneca Inc. (hereinafter for this document, "Zeneca Pharmaceuticals") certifies that U.S. Patent No. 4,935,437, information relative to which has previously been submitted, claims the change in ARIMDEX® (anastrozole) which is the subject of this supplemental new drug application.



PAUL DENERLEY, Ph.D.

B. EXCLUSIVITY INFORMATION

(1) Exclusivity Claim

Zeneca Pharmaceuticals claims an exclusivity period of three years for the change in ARIMIDEX[®] (anastrozole) presented in this supplemental new drug application.

(2) Authority for Exclusivity Claim

Exclusivity for the change in ARIMIDEX[®] (anastrozole) presented in this supplemental new drug application is being claimed pursuant to 21 CFR Section 314.108(b)(5).

(3) Information Demonstrating this Supplemental Application Contains New Clinical Investigations Conducted or Sponsored by the Applicant that are Essential to the Approval of this Supplemental New Drug Application.

a) Certification of New Clinical Investigations

Zeneca Pharmaceuticals certifies that to the best of Zeneca Pharmaceuticals' knowledge, each of the clinical investigations included in this supplemental new drug application meets the definition of "new clinical investigation" set forth in 21 CFR Section 314.108(a).



Mark Steinberg, MD
Global Project Team Physician

b) **Essential to Approval**

(i) **Literature Search**

Attached as Exhibit A is a list of all published studies and publicly available reports of clinical investigations known to Zeneca Pharmaceuticals through a literature search that are relevant to the conditions for which Zeneca Pharmaceuticals is seeking approval.

(ii) **Certification**

Zeneca Pharmaceuticals certifies that Zeneca Pharmaceuticals has thoroughly searched the scientific literature and, to the best of Zeneca Pharmaceuticals' knowledge, the list of relevant published studies and/or publicly available reports is complete and accurate, and in Zeneca Pharmaceuticals' opinion, such published studies and/or publicly available reports do not provide a sufficient basis for the approval of the conditions for which Zeneca Pharmaceuticals is seeking approval without reference to the new clinical investigation(s) in this supplemental new drug application.



Mark Steinberg, MD
Global Project Team Physician

(iii) **Explanation**

The listed published studies and/or publicly available reports of clinical investigations do not provide sufficient basis for the approval of the conditions for which Zeneca Pharmaceuticals is seeking approval, without reference to the new clinical investigations in this supplemental new drug application.

Zeneca believes that the listed published studies and/or data publicly available in literature reports of clinical investigations do not contain sufficient basis for the approval of ARIMDEX 1 mg for the treatment of advanced breast cancer in post-menopausal women for the following reasons:

The literature reports of ARIMDEX studies refer to its use as a second line agent.

There are no literature reports of studies comparing any selective oral aromatase inhibitor to tamoxifen in the literature. Tamoxifen is considered the standard first-line therapy of advanced breast cancer and there are no other agents currently approved for this indication.

The core clinical studies 1033IL/0030 and 1033IL/0027 are adequate and well controlled, similarly designed multicenter trials. These trials enrolled 1021 post-menopausal women and demonstrated the equivalence of ARIMIDEX and tamoxifen in the two primary endpoints of time to progression and response rate. In these trials ARIMIDEX was well tolerated and adverse events were usually mild-to-moderate.

The results from trials 1033IL/0030 and 1033IL/0027 established the value of ARIMIDEX for the treatment of advanced breast cancer in post-menopausal women. The pharmacology of ARIMIDEX and resulting safety profile may be a clinical advantage in certain patients, such as those with a history of thromboembolic disease, or an intact uterus.

The efficacy and safety results from these trials have not been published in the literature. Therefore, the overall conclusions regarding the use of ARIMIDEX as a first-line treatment of advanced breast cancer could not have been made by reference to the literature alone.

c. **Conducted or Sponsored by the Applicant.**

The new clinical investigations contained within this supplemental new drug application were conducted or sponsored by Zeneca Ltd. Attached as Exhibit B is a statement from a certified public accountant which establishes that Zeneca Ltd. has provided greater than 50% of the cost for the conduct of these new clinical investigations.

EXHIBIT A

BIBLIOGRAPHY

Buzdar A, Jonat W, Howell A, Jones S E, Blomqvist C, Vogel C, et al Study Group. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials. *Journal of Clinical Oncology* 1996;14(7):2000-2011.

Buzdar A, Jonat W, Howell A, Jones S, Blomqvist C, Vogel C, et al Study Group. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma. results of a survival update based on a combined analysis of data from two mature phase III trials. *Cancer* 1998; 83(8):1142-1152. Erratum: *Ibid* 1999 85 (4) pp 1010.

Buzdar A, Jones S, Vogel C, Wolter J, Plourde P, Webster A, Study Group. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. *Cancer* 1997;79(4):730-739.

Jonat W, Howell A, Blomqvist C, Eiermann W, Winblad G, Tyrrell C, et al, Study Group. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole ('Arimidex') with megestrol acetate in postmenopausal patients with advanced breast cancer. *European Journal of Cancer Part A* 1996;32A(3):404-412.

September 10, 1999

The Board of Directors
ZENECA Inc.

As required in Item 13 of the Supplemental New Drug Application (sNDA), this is to attest that for Arimidex® (anastrozole) 1 mg daily, ZENECA Ltd., as applicant for the sNDA, has provided greater than fifty percent of the cost of conducting clinical investigations essential to the approval of the sNDA, even though not all of the studies included in the sNDA were conducted under the IND.



Chris D Degan, CPA
Head, R&D Finance, Wilmington

CDD:lbt

EXCLUSIVITY SUMMARY FOR NDA # 20-541 SUPPL # S-006

Trade Name ARIMIDEX Tablets Generic Name Anastrozole

Applicant Name AstraZeneca Pharm HFD # 150

Approval Date If Known _____

PART I IS AN EXCLUSIVITY DETERMINATION NEEDED?

1. An exclusivity determination will be made for all original applications, but only for certain supplements. Complete PARTS II and III of this Exclusivity Summary only if you answer "yes" to one or more of the following question about the submission.

a) Is it an original NDA?
YES / / NO / X /

b) Is it an effectiveness supplement?

YES / X / NO / /

If yes, what type? (SE1, SE2, etc.) SE1

c) Did it require the review of clinical data other than to support a safety claim or change in labeling related to safety? (If it required review only of bioavailability or bioequivalence data, answer "no.")

YES / X / NO / /

If your answer is "no" because you believe the study is a bioavailability study and, therefore, not eligible for exclusivity, EXPLAIN why it is a bioavailability study, including your reasons for disagreeing with any arguments made by the applicant that the study was not simply a bioavailability study.

If it is a supplement requiring the review of clinical data but it is not an effectiveness supplement, describe the change or claim that is supported by the clinical data:

d) Did the applicant request exclusivity?

YES / X / NO / ___ /

If the answer to (d) is "yes," how many years of exclusivity did the applicant request?

3

e) Has pediatric exclusivity been granted for this Active Moiety?

NO

IF YOU HAVE ANSWERED "NO" TO ALL OF THE ABOVE QUESTIONS, GO DIRECTLY TO THE SIGNATURE BLOCKS ON PAGE 8.

2. Has a product with the same active ingredient(s), dosage form, strength, route of administration, and dosing schedule, previously been approved by FDA for the same use? (Rx to OTC switches should be answered NO-please indicate as such)

YES / ___ / NO / X /

If yes, NDA # _____ Drug Name _____

IF THE ANSWER TO QUESTION 2 IS "YES," GO DIRECTLY TO THE SIGNATURE BLOCKS ON PAGE 8.

3. Is this drug product or indication a DESI upgrade?

YES / ___ / NO / X /

IF THE ANSWER TO QUESTION 3 IS "YES," GO DIRECTLY TO THE SIGNATURE BLOCKS ON PAGE 8 (even if a study was required for the upgrade).

PART II FIVE-YEAR EXCLUSIVITY FOR NEW CHEMICAL ENTITIES

(Answer either #1 or #2 as appropriate)

1. Single active ingredient product.

Has FDA previously approved under section 505 of the Act any drug product containing the same active moiety as the drug under consideration? Answer "yes" if the active moiety (including other esterified forms, salts, complexes, chelates or clathrates) has been previously approved, but this particular form of the active moiety, e.g., this particular ester or salt (including salts with hydrogen or coordination bonding) or other non-covalent derivative (such as a complex, chelate, or clathrate) has not been approved. Answer "no" if the compound requires metabolic conversion (other than deesterification of an esterified form of the drug) to produce an already approved active moiety.

YES / X / NO / ___ /

If "yes," identify the approved drug product(s) containing the active moiety, and, if known, the NDA #(s).

NDA# 20-541 ARIMIDEX

NDA# _____

NDA# _____

2. Combination product.

If the product contains more than one active moiety (as defined in Part II, #1), has FDA previously approved an application under section 505 containing any one of the active moieties in the drug product? If, for example, the combination contains one never-before-approved active moiety and one previously approved active moiety, answer "yes." (An active moiety that is marketed under an OTC monograph, but that was never approved under an NDA, is considered not previously approved.)

YES / / NO / /

If "yes," identify the approved drug product(s) containing the active moiety, and, if known, the NDA #(s).

NDA# _____

NDA# _____

NDA# _____

IF THE ANSWER TO QUESTION 1 OR 2 UNDER PART II IS "NO," GO DIRECTLY TO THE SIGNATURE BLOCKS ON PAGE 8. IF "YES" GO TO PART III.

PART III THREE-YEAR EXCLUSIVITY FOR NDA'S AND SUPPLEMENTS

To qualify for three years of exclusivity, an application or supplement must contain "reports of new clinical investigations (other than bioavailability studies) essential to the approval of the application and conducted or sponsored by the applicant." This section should be completed only if the answer to PART II, Question 1 or 2 was "yes."

1. Does the application contain reports of clinical investigations? (The Agency interprets "clinical investigations" to mean investigations conducted on humans other than bioavailability studies.) If the application contains clinical investigations only by virtue of a right of reference to clinical investigations in another application, answer "yes," then skip to question 3(a). If the answer to 3(a) is "yes" for any investigation referred to in another application, do not complete remainder of summary for that investigation.

YES / / NO / /

IF "NO," GO DIRECTLY TO THE SIGNATURE BLOCKS ON PAGE 8.

2. A clinical investigation is "essential to the approval" if the Agency could not have approved the application or supplement without relying on that investigation. Thus, the investigation is not essential to the approval if 1) no clinical investigation is necessary to support the supplement or application in light of previously approved applications (i.e., information other than clinical trials, such as bioavailability data, would be sufficient to provide a basis for approval as an ANDA or 505(b)(2) application because of what is already known about a previously approved product), or 2) there are published reports of studies (other than those conducted or sponsored by the applicant) or other publicly available data that independently would have been sufficient to support approval of the application, without reference to the clinical investigation submitted in the application.

(a) In light of previously approved applications, is a clinical investigation (either conducted by the applicant or available from some other source, including the published literature) necessary to support approval of the application or supplement?

YES / / NO / /

If "no," state the basis for your conclusion that a clinical trial is not necessary for approval AND GO DIRECTLY TO SIGNATURE BLOCK ON PAGE 8:

(b) Did the applicant submit a list of published studies relevant to the safety and effectiveness of this drug product and a statement that the publicly available data would not independently support approval of the application?

YES / / NO / /

(1) If the answer to 2(b) is "yes," do you personally know of any reason to disagree with the applicant's conclusion? If not applicable, answer NO.

YES / / NO / /

If yes, explain: _____

(2) If the answer to 2(b) is "no," are you aware of published studies not conducted or sponsored by the applicant or other publicly available data that could independently demonstrate the safety and effectiveness of this drug product?

YES / / NO / X /

If yes, explain: _____

(c) If the answers to (b)(1) and (b)(2) were both "no," identify the clinical investigations submitted in the application that are essential to the approval:

 27

 30

Studies comparing two products with the same ingredient(s) are considered to be bioavailability studies for the purpose of this section.

3. In addition to being essential, investigations must be "new" to support exclusivity. The agency interprets "new clinical investigation" to mean an investigation that 1) has not been relied on by the agency to demonstrate the effectiveness of a previously approved drug for any indication and 2) does not duplicate the results of another investigation that was relied on by the agency to demonstrate the effectiveness of a previously approved drug product, i.e., does not redemonstrate something the agency considers to have been demonstrated in an already approved application.

a) For each investigation identified as "essential to the approval," has the investigation been relied on by the agency to demonstrate the effectiveness of a previously approved drug product? (If the investigation was relied on only to support the safety of a previously approved drug, answer "no.")

Investigation #1 27 YES / / NO / /

Investigation #2 30 YES / / NO / /

If you have answered "yes" for one or more investigations, identify each such investigation and the NDA in which each was relied upon:

b) For each investigation identified as "essential to the approval", does the investigation duplicate the results of another investigation that was relied on by the agency to support the effectiveness of a previously approved drug product?

Investigation #1 YES / / NO / /

Investigation #2 YES / / NO / /

If you have answered "yes" for one or more investigation, identify the NDA in which a similar investigation was relied on:

c) If the answers to 3(a) and 3(b) are no, identify each "new" investigation in the application or supplement that is essential to the approval (i.e., the investigations listed in #2(c), less any that are not "new"):

1033IL/0027 & 1033IL/0030

4. To be eligible for exclusivity, a new investigation that is essential to approval must also have been conducted or sponsored by the applicant. An investigation was "conducted or sponsored by" the applicant if, before or during the conduct of the investigation, 1) the applicant was the sponsor of the IND named in the form FDA 1571 filed with the Agency, or 2) the applicant (or its predecessor in interest) provided substantial support for the study. Ordinarily, substantial support will mean providing 50 percent or more of the cost of the study.

a) For each investigation identified in response to question 3(c): if the investigation was carried out under an IND, was the applicant identified on the FDA 1571 as the sponsor?

Investigation #1 !
 IND # _____ / X / ! NO / ___ / Explain: _____
 ! _____
 ! _____

Investigation #2 !
 IND # _____ YES / X / ! NO / ___ / Explain: _____

(b) For each investigation not carried out under an IND or for which the applicant was not identified as the sponsor, did the applicant certify that it or the applicant's predecessor in interest provided substantial support for the study?

Investigation #1 !
 YES / ___ / Explain _____ ! NO / ___ / Explain _____
 ! _____
 ! _____

Investigation #2 !
 YES / ___ / Explain _____ ! NO / ___ / Explain _____
 ! _____
 ! _____

(c) Notwithstanding an answer of "yes" to (a) or (b), are there other reasons to believe that the applicant should not be credited with having "conducted or sponsored" the study? (Purchased studies may not be used as the basis for exclusivity. However, if all rights to the drug are purchased (not just studies on the drug), the applicant may be considered to have sponsored or conducted the studies sponsored or conducted by its predecessor in interest.)

YES / /

NO / X /

If yes, explain: _____

/S/

8/30/00

Signature

Date

Title: Project manager

/S/

9/1/00

Signature of Office/
Division Director

Date

cc: Original NDA

Division File

HFD-93 Mary Ann Holovac

ARIMIDEX™ (anastrozole)

DEBARMENT CERTIFICATION

For further information regarding this section, please contact:

Laura E. García-Davenport, M.S.
Senior Regulatory Project Manager
(302) 886-7533
Zeneca Pharmaceuticals
A Business Unit of Zeneca Inc.
1800 Concord Pike
PO Box 15437
Wilmington, DE 19850-5437

ARIMIDEX is a trademark, the property of Zeneca Limited.

ZENECA
Pharmaceuticals
A Business Unit of Zeneca Inc.


1800 Concord Pike
PO Box 15437
Wilmington, DE 19850-5437

NOV 0 1 1999

Re: ARIMIDEX® (anastrozole)
NDA 20-541
First-Line Supplemental

In response to the requirements of the Generic Drug Enforcement Act of 1992, I hereby certify on behalf of Zeneca Pharmaceuticals, a Business Unit of Zeneca Inc., that we did not use and will not use in connection with this application, the services of any person in any capacity debarred under section 306 (a) or (b).

Sincerely,



Sandra L. Bihary
Executive Director
Regulatory Affairs Department
(302) 886-2192
(302) 886-2822 (fax)

SLB/LGD/jr

FINANCIAL

DISCLOSURE

addition of 1 subject (Subject 0027/0103/0102) who was given tamoxifen and had a serious event of vomiting that led to withdrawal from treatment.

A total of 207 subjects had serious adverse events, which represents an increase of 21 subjects from the time of the ISS data cutoff. The overall incidence of serious adverse events in the core controlled trials was similar between the treatment groups (19.0% of subjects who were given anastrozole and 21.7% of subjects who were given tamoxifen). Most serious adverse events were not related to trial treatment. The only serious drug related adverse event that was reported by more than 1 additional subject since the time of the ISS data cutoff was vaginal hemorrhage (3 [0.6%] subjects total, all of whom were given tamoxifen).

12.3 Conclusion of 120 day safety update

On the basis of the data presented in the ISS and this 4MSU, the sponsor recommends that the following additions be made to the prescribing information for Arimidex.

Possible adverse reactions: "ARIMIDEX may be associated with joint pain/stiffness."

13.0 FINANCIAL DISCLOSURE

Protocol 0027 was conducted outside North America. There were 83 centers and a total number of 101 investigators at those centers. 48 investigators responded to the sponsor's inquiry concerning Financial Disclosure. All 48 investigators indicated no existing financial arrangement with the sponsor. 53 investigators have failed to report to requests from the sponsor for financial disclosure. The sponsor however claims no payment is identified in corporate accounting records concerning payment by sponsors to these investigators.

Protocol 0030 was conducted at 97 centers in North America. There was a total of 26 Principal investigators and 727 sub-investigators at those centers All 26 Principal investigators and 105 sub-investigators responded to the sponsor's inquiry concerning Financial Disclosure, and all but two indicate no existing financial arrangement with the sponsor. 621 sub-investigators have failed to respond to requests from the sponsor for financial disclosure. The sponsor however claims no payment to these sub-investigators is identified in corporate accounting records.

For protocol 0030 one investigator reported a financial interest, but only 9 patients were entered at that center. One sub-investigator reported a financial interest, but no patients were entered at that center.

14.0 LABELING

The labeling proposed by the applicant has been revised by the review team. See separate Labeling document.

CERTIFICATION: FINANCIAL INTERESTS AND ARRANGEMENTS OF CLINICAL INVESTIGATORS

TO BE COMPLETED BY APPLICANT


With respect to all covered clinical studies (or specific clinical studies listed below (if appropriate)) submitted in support of this application, I certify to one of the statements below as appropriate. I understand that this certification is made in compliance with 21 CFR part 54 and that for the purposes of this statement, a clinical investigator includes the spouse and each dependent child of the investigator as defined in 21 CFR 54.2(d).

Please mark the applicable checkbox.

- (1) As the sponsor of the submitted studies, I certify that I have not entered into any financial arrangement with the listed clinical investigators (enter names of clinical investigators below or attach list of names to this form) whereby the value of compensation to the investigator could be affected by the outcome of the study as defined in 21 CFR 54.2(a). I also certify that each listed clinical investigator required to disclose to the sponsor whether the investigator had a proprietary interest in this product or a significant equity in the sponsor as defined in 21 CFR 54.2(b) did not disclose any such interests. I further certify that no listed investigator was the recipient of significant payments of other sorts as defined in 21 CFR 54.2(f).

Clinical Investigators	Please see attached reports.	

- (2) As the applicant who is submitting a study or studies sponsored by a firm or party other than the applicant, I certify that based on information obtained from the sponsor or from participating clinical investigators, the listed clinical investigators (attach list of names to this form) did not participate in any financial arrangement with the sponsor of a covered study whereby the value of compensation to the investigator for conducting the study could be affected by the outcome of the study (as defined in 21 CFR 54.2(a)); had no proprietary interest in this product or significant equity interest in the sponsor of the covered study (as defined in 21 CFR 54.2(b)); and was not the recipient of significant payments of other sorts (as defined in 21 CFR 54.2(f)).
- (3) As the applicant who is submitting a study or studies sponsored by a firm or party other than the applicant, I certify that I have acted with due diligence to obtain from the listed clinical investigators (attach list of names) or from the sponsor the information required under 54.4 and it was not possible to do so. The reason why this information could not be obtained is attached.

NAME John G. Goddard	TITLE Vice President, Finance & Chief Financial Officer
FIRM/ORGANIZATION Zeneca, Inc.	
SIGNATURE 	DATE 9/29/99

Paperwork Reduction Act Statement

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Public reporting burden for this collection of information is estimated to average 1 hour per response, including time for reviewing instructions, searching existing data sources, gathering and maintaining the necessary data, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information to the address to the right:

Department of Health and Human Services
Food and Drug Administration
5600 Fishers Lane, Room 14C-03
Rockville, MD 20857

Trial 1033IL/0027 ~ Replied to Request for Disclosure.

No Financial Arrangements

Name	Address
Prof. S Van Belle/Veronique Cocquit	Dienst Oncologie UZ Gent De Pintelaan 185 9000 Gent, BELGIUM
Prof. Vergote	Dienst Gynaecologische Oncologie KUL Gasthuisberg Herestraat 49 3000 Leuven BELGIUM
Dr A Malzyner	Av. Nove de Julio, 4644 Sao Paulo-SP CEP 01406 - 100 BRAZIL
Dr Bohuslav Konopasek	Onkologicka klinika University Karlovy 1 lekarska fakulta U nemocnice 2, 128 08 Praha 2, CZECH REPUBLIC
Dr Otakar Bednarik	Masarykov onkologicky ustav Oddeleni klinicke onkologie I Zlutý kopec 7 656 53 Brno, CZECH REPUBLIC
Prof F Given	Dept. of Surgery Clinical Sciences Building University College Hospital Galway IRELAND
Professor J Bonneterre	Centre Oscar Lambret Rue Frederic Combemale BP 307 F59020 Lille Cedex, FRANCE

9/27/99

No Financial Arrangements

Name	Address
Dr D Langlois	Centre St Michel 21 Rue du General Dumont 17000 La Rochelle FRANCE
Dr Daniel Serin	Clinique Ste Catherine Chemin du Lavarin BP859 84003 Avignon, FRANCE
Prof. Bergerat	Service d'Oncologie 1, Place de l'Hopital 67091 Strasbourg France
Dr Maria Rios	Centre Alexis Vautrin Avenue de Bourgogne 54511 Vandoeuvre les Nancy FRANCE
Dr Louis Mauriac	Institut Bergonie 180 rue Saint Genes 33076 Bordeaux Cedex FRANCE
Dr E Merkle	Chefaerztin der Frauenklinik Olgohospital/Frauenklinik Berg Obere Str. 270190 Stuttgart GERMANY
Prof W Kleine	Univeritaets-Frauenklinik Hugstetter str.55 D-79106 Freiburg GERMANY
Dr Tamas Nagykalmi	Dept of Oncoradiology Uzsoki u Hospital Uzsoki u 29 11-1145 Budapest, HUNGARY

Trial 1033IL/0027 ~ Replied to Request for Disclosure.

No Financial Arrangements

Name	Address
Dr Tamas Pinter	Dept of Oncoradiology Petz Aladar County Hospital Zrinyi u 14 H-9024 Gyor, HUNGARY
Prof. F Boccardo	Primario Divisione Oncologia Medica IIIstituto Nazionale per la Ricerca sul Cancro Genova ITALY
Prof. C Bumma	Primario Divisione di Oncologia Medica Ospedale S. Giovanni Torino, ITALY
Dr G Brignone	Primario Divisione Oncologia Servizio di oncologia Ospedale M Ascolivia Carmelo Lazzaro, Palermo ITALY
Dr J De La Garza	Instituto Nacional de Cancerologia Av San Fernando 22 Colonia Tlalpan MEXICO DF CP 14000
Dr Eduardo Maafs-Molina	Clinica Londres Durango 50, Col. Roma MEXICO DF 06700
Dr J L Gonzales-Vela	Centro Medico Darox Calle Dr Martinez No.100 Depacho 202 A Col. Los Doctores Monterrey N.L. MEXICO

9/27/99

No Financial Arrangements

Name	Address
Dr Simon Allan	Regional Cancer Treatment Service Palmerston North Hospital Ruahine Street Palmerston North NEW ZEALAND
Dr Jerzy Zaluski	Centre of Oncology Maria Sklodowska-Curie Memorial Institute ul Garbary 15, 61 866 Poznan, POLAND
Dr Maciej Krzakowski	Maria Sklodowska-Curie Memorial Centre of Oncology Findera 101 02-781 Warsaw, POLAND
Dr Piotr Koralewski	L. Rydygier Memorial Hospital os. Zlotej Jesieni 1 31-826 Krakow POLAND
Dr A Maxwell	142 Chelmsford Road Berea 4001 SOUTH AFRICA
Dr G Landers	Medical Mews 7 Parklands Overport 4001 SOUTH AFRICA
Dr Goran Carlsson	Kirurgiska Kliniken Ostra sjukhuset S-416 85 Goteborg SWEDEN
Dr Jan-Henry Svensson	Onkologist kliniken Lasarettet S-501 82 Boras SWEDEN

9/27/99

Trial 1033IL/0027 ~ Replied to Request for Disclosure.

No Financial Arrangements

Name	Address
Dr Jörgen Hansen	Onkologkliniken Centrallasarettet 721 89 Vasteras SWEDEN
PD Dr Ch Rochlitz	Onkologie Kantonsspital Petersgraben 4 4031 Basel SWITZERLAND
Dr C Sessa	Servizio Oncologico cantonale Ospedale San Giovanni 6500 Bellinzona SWITZERLAND
Dr L Perey	Centre Pluridisciplinaire d'Oncologie Niveau 06 CHUV1011 Lausanne SWITZERLAND
PD Dr M Castiglione	Onkologische Abteilung Inselspital Freiburgstr. 18 3010 Bern SWITZERLAND
Dr C Keen	Maidstone Hospital Hermitage Lane Maidstone KENT ME16 9QQ UNITED KINGDOM
Mr C Humphrey	Department of Surgery Birch Hill Hospital Littleborough Rochdale Lancashire OL12 9QB, UNITED KINGDOM

9/27/99

Page 5

Trial 1033IL/0027 ~ Replied to Request for Disclosure.

No Financial Arrangements

Name	Address
Dr T W J Lennard	University of Newcastle Department of Surgery Medical School Framlington Place, Newcastle Upon Tyne NE2 4111 UNITED KINGDOM
Mr L C Barr	Nightingale Centre Withington Hospital Nell Lane West Didsbury, Manchester M20 8LR, UK
Dr A Stewart	Christie Hospital & Holt Radium Institute Wilmslow Road Manchester M20 8BX UNITED KINGDOM
Dr W P Abram	The Belvoir Park Hospital Hospital Road BELFAST BT8 8JR
Professor R W Blamey	City Hospital Hucknall Road Nottingham NG5 1PB UNITED KINGDOM
Mr C D M Griffith	Dept of Surgery Royal Victoria Hospital Queen Victoria Road Newcastle Upon Tyne NE1 4LP UNITED KINGDOM
Dr R C F Leonard	Dept of Clinical Oncology Western General Hospital Crewe Rd Edinburgh EH4 2XU UNITED KINGDOM

Trial 1033IL/0027 ~ Replied to Request for Disclosure.

No Financial Arrangements

Name	Address
Professor M B McIlmurray	Royal Lancaster Infirmary Ashton Road Lancaster Lancashire LA1 4RP, UNITED KINGDOM
Dr J Waxman	Department of Clinical Oncology Hammersmith Hospital Du Cane Road London W12 0NN
Mr S R Ebbs	Mayday University Hospital Mayday Road Thornton Heath Surrey, CR7 7YE, UNITED KINGDOM
Mr M Kissin	Royal Surrey County Hospital Egerton Road Guildford Surrey GU2 5XX UNITED KINGDOM

Trial 1033IL/0027 ~ No Response to Request for Disclosure as of the Date of this Report*

Name	Address
Dr Robert Tozzini	Instituto Mater Vitae de Ginecologia y Obstetrica Montevideo 2122 (2000) Rosario ,Provincia Santa Fe ARGENTINA
Dr A Nunez de Pierro	Hospital Fernandez Cervino 3356 14250 Buenos Aires ARGENTINA
Dr F Gago	Espejo 80 Planta Baja Dto. No:1 (5500) Mendoza ARGENTINA
Dr C Maanon	Hospital San Bernardo Sector: Oncologia Clinica Virrey Tolado 694 - Salta (4400) Provincia de Salta ARGENTINA
Dr Jane McNeil Beith	Oncology Dept. Royal Prince Alfred Hospital Missenden Road Camperdown NSW 2050 AUSTRALIA
Michael Green	Oncology Dept. Royal Melbourne Hospital Grattan Street Parkville 3052 AUSTRALIA
Dr Michael Byrne	Oncology Dept. Sir Charles Gairdner Hospital Verdun Street Nedlands 6009 AUSTRALIA

*Indicates no sponsor payments identified by corporate accounting records.

10/07/99

Trial 1033IL/0027 ~ No Response to Request for Disclosure as of the Date of this Report*

Name	Address
Dr J. Janssens	Salvatorziekenhuis Salvatorstraat 20 2500 Hasselt BELGIUM
Dr. G De Wasch	Henri Serruys Ziekenhuis Kairostraat 84 8400 Oostende BELGIUM
Dr A Barros	Womans Reference Centre Av Brigadeiro Luis Antonio 849-4 Andar Sao Paulo-SP CEP 01317.001 BRAZIL
Dr A L Frasson	Catholique University (PUC) Av. Ipiranga, 6690-C3 714 Porto Alegre - RS CEP: 90610-000, BRAZIL
Dr C Tosello de Oliveira	Brazilian Institute for Combat to Cancer Avenida Alcantara Machado 2576 Sao Paulo BRAZIL
Dr Pavel Vodvarka (Previously Dr Franrisek Beska, until 9/1/97)	Radioterapeuticka klinika Trida 17 listopadu 1790 Fakultni Nemocnice Ostrava-Poruba 718 00 Ostrava-Poruba, CZECH REPUBLIC
Dr Jan Fischer	Onkologicke oddeleni Nemocnice v Ceskych Budejovicich Bozeny Nemcove 54 370 87 Ceske Budejovice CZECH REPUBLIC

*Indicates no sponsor payments identified by corporate accounting records.

10/07/99

Trial 1033IL/0027 ~ No Response to Request for Disclosure as of the Date of this Report*

Name	Address
Dr Jindrich Machacek	Onkologicka klinika Fakultni nemocnice IP Pavlova 6 775 20 Olomouc, CZECH REPUBLIC
Dr. Alena Jelinkova	Poliklinicke oddeleni klinicke onkologie Nemocnice s poliklinikou J.E. Purkyně 270/5 434 64 Most, CZECH REPUBLIC
Dr Maria Wagnerova	Klinika radioterapie a onkologie Fakultna nemocnica L. Pasteura Rastislavova 43 041 90 Kosice SLOVAKIA
Dr Lubomir Bohunicky	Narodny onkologicky ustav National Cancer Institute Klenova 1 833 10 Bratislava, SLOVAKIA
Dr Philippe Chollet	Centre Jean Perrin 30 Place Henri Dunant BP 392 63011 Clermont Ferrand Cedex, FRANCE
Dr E Vuillemin	Centre St Yves 20 Rue des freres Texier La Houlle 56000 Vannes FRANCE
Prof Michele Tubiana-Hulin	Centre Rene Higuenin 35 Rue Dailly 92211 Saint Cloud FRANCE

*Indicates no sponsor payments identified by corporate accounting records.

Trial 1033IL/0027 ~ No Response to Request for Disclosure as of the Date of this Report*

Name	Address
Prof Tulusan	Frauenheilkunde und Geb.-Hilfe Kinikum Bayreuth D-95445 Bayreuth GERMANY
Prof. J Hilfrich	Gynakologie Henriettenstiftung Schwemannstr. 17 D-30559 Hannover GERMANY
Prof W Eiermann	Frauenklinik vom Roten Kreuz Taxisstr. 3 D-80637 Muenchen GERMANY
Prof W Jonat	Universitatsklinik Klinik fur Frauenheil Michaelisstr.16 24105 Kiel, GERMANY
Dr Med Klaus Kuhndel (Formerly Dr Kohler)	Univ. Frauenklinik Leipzig Philipp-Rosenthal-Str.55 04103 Leipzig GERMANY
Dr. Schoenneg	Kurfurstendam 216 10719 Berlin GERMANY
Dr F. Kettner	Staetisches klinikum Madgeburg Haematologisch Abteilung Max-otten Str 11- 15 39104 Madgeburg GERMANY

*Indicates no sponsor payments identified by corporate accounting records.

10/07/99

Trial 1033IL/0027 ~ No Response to Request for Disclosure as of the Date of this Report*

Name	Address
Dr A Keramopoulos	Alexandras Hospital Vas. Sofina 80 and K. Lourou 115 28 Athens GREECE
Dr Istvan Szakolczai	National Institute of Oncology Rath Gy u 7-9 H-1122 BUDAPEST, HUNGARY
Dr Janos Szanto	B-A-Z County Hospital Szentpeteri kapu 76 H-3501 HUNGARY
Dr Jozsef Erfan	Josa A. County Hospital NYIREGYHAZA Szent Istvan u 68. H-4400, HUNGARY
Dr Alberto Scanni	Primario Divisione Oncologia Ospedale Fatebenefratelli 20121 Milano ITALY
Dr V L Puerto	Centro Medico Nacional S XXI Hospital Oncologia Av Cuauhtemoc 330 Colonia Doctores, DF CP 06720, MEXICO
Dr G Morgan-Villela	Centro Medico Naolonal de Occidente Belisario Dominguez No.1000 Col. Independencia Guadalajara, Jalisco CP 44380, MEXICO

*Indicates no sponsor payments identified by corporate accounting records.

10/07/99

Trial 1033IL/0027 ~ No Response to Request for Disclosure as of the Date of this Report*

Name	Address
Dr Bozena Karczmarek-Borowska	Regional Oncology Centre Jaczewskiego 7 St 20-090 Lublin POLAND
Professor Carlos de Oliveira	Hospitais de Universidade de Coimbra Avenida Bissau Barreto 3000 Coimbra PORTUGAL
Dr Maria Jose Passos	Instituto Portugues de Oncologia Rua Professor Lima Bastos 1070 Lisboa PORTUGAL
Dr Joaquim Gouveia	Hospital de Santo Antonio dos Capuchos Alameda Santo Antonio dos Capuchos 1100 Lisboa PORTUGAL
Dr Mauricio Chumbo	Hospital "Condes de Castro Guimaraes" Unidade de Oncologia Travessa da Conceicao No:1 2750 Cascais PORTUGAL
Dr Bruno da Costa / Dr Ricardo da Luz	Unidade de Oncologia Medica Servico de Medicina 2 Hospital de Santa Maria 1699 Lisboa Codex PORTUGAL
Dr Hakan Salander	Kirurgiska Kliniken Lanssjukhuset 461 85 Trollhattan

*Indicates no sponsor payments identified by corporate accounting records.

10/07/99

Trial 1033IL/0027 ~ No Response to Request for Disclosure as of the Date of this Report*

Name	Address
Ass Prof Per-Ebbe Jonsson	Kirurgiska kliniken Lasarettet S-251 87 Helsingborg SWEDEN
Ass Prof Gunnar Westman	Onkologiska Kliniken Regionsjukhuset S-701 85 Orebro SWEDEN
Dr B Thuerlimann	Medizinische Klinik C Kantonsspital 9007 St. Gallen SWITZERLAND
Prof. Dr. Dincer Firat	Hacettepe University Faculty of Medicine Medical Oncology Department Ankara TURKEY
Prof. Dr. S Okkan	Istanbul University Cerrahpasa Faculty of Medicine Radiation Oncology Department Istanbul TURKEY
Prof Dr Suheyla Serdengeçti	Istanbul University Cerrahpasa Faculty of Medicine Medical Oncology Department Istanbul TURKEY
Mr R Hall	York District Hospital Wigginton Road York YO3 7HE UNITED KINGDOM

*Indicates no sponsor payments identified by corporate accounting records.

10/07/99

Trial 1033IL/0027 ~ No Response to Request for Disclosure as of the Date of this Report*

Name	Address
Mr J H R Winstanley	Royal Liverpool University Hospital Prescot Street Liverpool L7 8XP UNITED KINGDOM
Dr D J Dodwell	Cookridge Hospital Leeds LS16 6QB UNITED KINGDOM
Dr C J Tyrell	Department of Radiotherapy Plymouth General Hospital Freedom Fields Plymouth, Devon, PL4 7JJ, UNITED KINGDOM
Mr A Wilson	Whittington Hospital Highgate Hill London N19 5NF UNITED KINGDOM

*Indicates no sponsor payments identified by corporate accounting records.

10/07/99

Trial 1033IL/0030 ~ Replied to Request for Disclosure

NO FINANCIAL ARRANGEMENTS

Name	Facility	address 1	address 2	address 3	City, State, Zip
Aman U. Buzdar, MD	MD Anderson Cancer Center	University of Texas	Box 56	1515 Holcombe Boulevard	Houston, TX 77030
Karl K. Boatman, MD	INTEGRIS Oncology Services		Box 100 4210	3300 NW Expressway	Oklahoma City, OK 73112-4481
Peter Bushunow, MD	Rochester General Hospital	Department of Medicine		1425 Portland Avenue	Rochester, NY 14621-3001
Nikolay V. Dimitrov, MD	Michigan State University	Department of Medicine	B-338 Clinical Center		East Lansing, MI 48824-1317
Carol J. Fabian, MD	University of Kansas Medical Center	Division of Clinical Oncology		3901 Rainbow Blvd.	Kansas City, KS 66160-7353
Michael Ward, MD	Medical Arts Clinic		Suite 100	4102 24th Street	Lubbock, TX 79410
Nagendra Tirumali, MD	Hematology/Oncology, Kaiser Permanente	Central Interstate Medical Office	1st Floor	3600 N. Interstate Ave	Portland, OR 97227-1191
Richard Koslerowski, MD	North Penn Hospital			100 Medical Campus Dr	Lansdale, PA 19446
Sanford J. Kempin, MD	Desert Hospital	Comprehensive Cancer Center	Suite E 320	1180 N. Indian Canyon Dr	Palm Springs, CA 92262
Gary Burton, MD	Louisiana State Univ Medical Center	Department of Medicine	PO Box 33932	1501 Kings Highway	Shreveport, LA 71130-3932
Gershon Y. Locker, MD	Evanston Northwestern Healthcare	Kellogg Cancer Care Center		2650 Ridge Avenue	Evanston, IL 60201
James A. Mallard, MD	Creighton Cancer Center			601 North 30th Street	Omaha, NE 68131
Aroop Mangalik, MD	University of New Mexico	Cancer Research & Treatment Center		900 Camino de Salud, NE	Albuquerque, NM 87131
Michael W. Meshad, MD	Providence Hospital		Suite A208	6701 Airport Boulevard	Mobile, AL 36608
David B. Myers, MD	Billings Interhospital Oncology Project		Suite #2	1239 North 28th Street	Billings, MT 59101
Elizabeth Reed, MD	Univ of Nebraska Medical Center	Dept of Hematology & Oncology	PO Box 983330	600 South 42nd Street	Omaha, NE 68198-3330

Trial 1035IL/0030 ~ Replied to Request for Disclosure

NO FINANCIAL ARRANGEMENTS

Name	Facility	address 1	address 2	address 3	City, State, Zip
Gregory Sama, MD	Cedars Sinai	Comprehensive Cancer Center	-	8700 Beverly Boulevard	Los Angeles, CA 90048
Harvey B. Sher, MD	Jacksonville Oncology Group	-	-	6629 Beach Boulevard	Jacksonville, FL 32216-2816
Peter T. Silberstein, MD	North Iowa Mercy Health Center	Mercy Cancer Center	-	1000 4th Street SW	Mason City, IA 50401
Mary A. Simmonds, MD, FACP	Central PA Hema & Med Oncol Assoc	-	-	50 North 12th Street	Lemoyne, PA 17043
Katherine Tkaczuk, MD	University of Maryland Cancer Center	-	-	22 South Greene Street	Baltimore, MD 21201
Debasish Tripathy, MD	UCSF Mount Zion Cancer Center	Breast Care Center	- 6th Floor	2356 Sutter Street	San Francisco, CA 94115
Robert Hirsch, MD	-	-	- Suite 200	2400 North University Dr	Pembroke Pines, FL 33024
Janet Wolter, MD	Rush-Presbyterian-St Lukes Med Center	Professional Bldg II	, Suite 821	1725 West Harrison St	Chicago, IL 60612
Michael S. Entmacher, MD	Fox Chase Cancer Center at	Memorial Hosp of Burlington Co	- 4 Stokes	175 Madison Avenue	Mt Holly, NJ 08060
Nicholas Robert, MD	Fairfax Prince William	Hematology/Oncology	- Suite 230	3289 Woodburn Road	Annandale, VA 22003-1296
Fred Kass, MD	Santa Barbara Hema/Oncol Med Group, Inc	Cancer Foundation of Santa Barbara	-	300 West Pueblo Street	Santa Barbara, CA 93105
Stefan Madajewicz, MD	University Hospital	Medical Oncology HSC T-17, 080	-	SUNY at Stony Brook	Stony Brook, NY 11794-8174
Ray H. Clark, MD	Hematology/Oncology Associates	-	- Suite 201	1100 East Michigan Ave	Jackson, MI 49201
Alan Kolctsky, MD	Comprehensive Cancer Center	-	-	21020 State Road 7	Boca Raton, FL 33428
Aaren Hoelzer, MD	c/o Joul Pappas (Research Office)	Memorial Medical Center	- Regional Cancer Center	701 North First Street	Springfield, IL 62781

Trial 1035IL/0030 ~ Replied to Request for Disclosure

NO FINANCIAL ARRANGEMENTS

Name	Facility	address 1	address 2	address 3	City, State, Zip
Stuart Tipping, MD	Marshfield Clinic	3A Oncology		1000 North Oak Avenue	Marshfield, WI 54449
Rebecca Moroose, MD	Florida Hospital		- Suite 289	2501 North Orange Av	Orlando, FL 32804
Jayne Gurtler, MD	Professional Medical Corporation		- Suite One	3939 Houma Blvd	Metairie, LA 70006
Pamela Crilley, DO	Allegheny Univ of the Health Sciences	Hahnemann Divison	- Mail Stop 412	Broad and Vine Streets	Philadelphia, PA 19102-1192
Allen M. Grossman, MD	Knoxville Hematology/Oncology Assoc		- Suite C	1114 Weisgarber Road	Knoxville, TN 37909
Sharon M. Ondreyco, MD	Palo Verde Hematology/Oncology Ltd		- Suite 106	5601 West Eagle	Glendale, AZ 85014
H. Peter DeGreen, MD	Lancaster Cancer Center Ltd			333 North Arch Street	Lancaster, PA 17603
Judie R. Goodman, DO	Providence Hospital		- 3rd Floor	22301 Foster Winter Drive	Southfield, MI 48075
William Popovic, MD	Oncology Care Center			4000 North Illinois	Belleville, IL 62226
Heldi Puc, MD	Hematology & Oncology Associates		- Suite 400	1000 East Genesee Street	Syracuse, NY 13210
Michael S. Roberts, MD	Hematology Associates Ltd		- Suite #501	3411 North 5th Avenue	Phoenix, AZ 85013-3897
Peter D. Byeff, MD	Hematology/Oncology		- Suite 1A	55 Meriden Avenue	Southington, CT 06489
Rita A. Blanchard, MD	Boston Medical Center	Medical Oncology Section	- Evans 556	88 East Newton Street	Boston, MA 02118
Jeremy K. Hon, MD	Comprehensive Cancer Care Institute		- Suite 200	201 Sivley Road	Huntsville, AL 35801
Antonius A. Miller, MD	University of Tennessee - Memphis	Division of Hematology & Oncology	- 3rd Floor - Health Science Cntr	3 North Dunlap	Memphis, TN 38163

Trial 1053IL/0030 ~ Replied to Request for Disclosure

NO FINANCIAL ARRANGEMENTS

Name	Facility	address 1	address 2	address 3	City, State, Zip
Timothy Woodlock, MD	St Marys Hospital			89 Genesee Street	Rochester, NY 14611
Samuel G. Taylor, MD	Illinois Masonic Cancer Center			901 West Wellington Avenue	Chicago, IL 60657
James T. May, MD	Hematology & Oncology Assoc of VA		- Suite 100	1807 Libbie Avenue	Richmond, VA 23226
Steven E. Come, MD	Beth Israel Deaconess Medical Center		- TCC 913C	330 Brookline Avenue	Boston, MA 02215
William F. Von Stubbe, MD	Valley Cancer Group	Internal Medicine Assoc of Yakima, Inc		316 Holton Avenue	Yakima, WA 98902
C. Eric Hartz, MD	Eastern Maine Medical Center	Cancer Care of Maine	- Suite 20	417 State Street	Bangor, ME 04401-6674
David L. Headley, DO	The Oncology Clinic, P.C.		- Suite 303	525 North Foote	Colorado Springs, CO 80909
William A. Cook, MD	St Vincents Hospital	Medical Center of New York	- NR 1411	153 West 11th Street	New York, NY 10011
Paula Silverman, MD	University Hospitals of Cleveland	Ireland Cancer Center		11100 Euclid Avenue	Cleveland, OH 44106-5055
Charles F. White, MD	Lahey Clinic	Department of Medical Oncology		41 Mall Road	Burlington, MA 01805
John Horton, MB ChB	Moffitt Cancer Center & Research Inst		- Room 3157	12902 Magnolia Drive	Tampa, FL 33612-9497
Ivan S. Lowenthal, MD	Northwestern Connecticut Oncology	and Hematology Associates		200 Kennedy Drive	Torrington, CT 06790
Robert J. Meister, MD	Arlington Fairfax Hematology Oncology		- Suite 307	1715 North George Mason Drive	Arlington, VA 22205
Shalendra Verma, MD	Ottawa Regional Cancer Center	Ottawa General Hospital Division		501 Smyth Road	Ottawa, Ontario K1H 8L6 CA
Eva Tomiak, MD	Ottawa Regional Cancer Center	Ottawa Civic Division		190 Melrose Avenue	Ottawa, Ontario K1Y 4K7 CA
Robert Myers, MD	Credit Valley Professional Building	Credit Valley Hospital	- Suite 509	2300 Eglinton Avenue West	Mississauga, Ontario L5M 2V8 CA

Trial 1033IL/0030 ~ Replied to Request for Disclosure

NO FINANCIAL ARRANGEMENTS

Name	Facility	address 1	address 2	address 3	City, State, Zip
David Bowman, MD	Manitoba Cancer Trtmt & Res Foundation			100 Olivia Street	Winnipeg, Manitoba R3E 0V9 CA
Margot Burnell, MD	St John Regional Hospital	Department of Oncology	PO Box 2100	400 University Avenue	Saint John, New Brunswick E2L 4L2 CA
David Holland, MD	Lethbridge Cancer Clinic		Room 2H209	960 19th Street South	Lethbridge, Alberta T1J 1W5 CA
Marla Tria Tirona, MD	Allan Blair Cancer Center			4101 Dewdney Avenue	Regina, Saskatchewan S4T 7T1 CA
Jean-Marc Nabholz, MD	Cross Cancer Institute	Department of Medicine		11560 University Avenue	Edmonton, Alberta T6G 1Z2 CA
Maureen Trudeau, MD	Women's College Hospital	Department of Oncology	Burton Hall, Room 519	60 Grosvenor Street	Toronto, Ontario M5S 1B6 CA
Jean Robert, MD	Hopital du Saint-Sacrement	Unite D'Oncologie		1050 Chemin Ste-Foy	Quebec City, Quebec G1S 4L8 CA
Michael Pollak, MD	Jewish General Hospital	Oncology Department		3755 Cote Ste Catherine Road	Montreal, Quebec H3T 1E2 CA
Martin Oken, MD	Virginia Piper Cancer Institute			800 East 28th Street	Minneapolis, MN 55407-3799
Lynn M. Schuchter, MD	Univ of Pennsylvania Cancer Center	Hematology-Oncology Division	Penn Tower - 6th Floor	3400 Spruce Street	Philadelphia, PA 19104-4236
Sharon J. Yee, MD			Suite 304	612 West Duarte Road	Arcadia, CA 91007
Joan E. Trey, MD	Metro Health Medical Center			2500 Metro Health Drive	Cleveland, OH 44109-1998
Chris Theodossiou, MD	Stanley S Scott Cancer Center	Louisiana State Univ Med Center	Suite 604K	1542 Tulane Avenue	New Orleans, LA 70112
Ellis Levine, MD	Roswell Park Cancer Institute	Division of Medicine		Elm and Carlton Streets	Buffalo, NY 14263-0001
Craig L. Reitz, MD			Suite 375	4205 McAuley Blvd	Oklahoma City, OK 73120

Trial 1055IL/0030 ~ Replied to Request for Disclosure

NO FINANCIAL ARRANGEMENTS

Name	Facility	address 1	address 2	address 3	City, State, Zip
Jack J. Sternberg, MD	Clinical Investigation Specialists, Inc		- Suite 300, Searcy Building	10809 Executive Center Drive	Little Rock, AR 72211
Bill L. Tranum, MD	Clinical Investigation Specialists, Inc		- Suite 300, Searcy Bldg	10809 Executive Center Drive	Little Rock, AR 72211
Frank Senecal, MD	Hematology Oncology Northwest, PC		- Suite 305	1624 South I Street	Tacoma, WA 98405
Robert O. Dillman, MD	Hoag Cancer Center		- Building 41	1 Hoag Drive	Newport Beach, CA 92663
Ann S. Kelley, MD	Ventura County Hematology-Oncology Spcists		- Suite 320	1700 North Rose Avenue	Oxnard, CA 93030
Bruce R. Piccone, DO	The Care Group, PC			1444 West Passyunk Avenue	Philadelphia, PA 19145
Tracey F. Welsberg, MD	Maine Center for Cancer Medicine			100 US Route One	Scarborough, ME 04074
Leslie R. Laufman, MD	Columbus CCOP	Community Clinical Oncology Program		1151 South High Street	Columbus, OH 43206
Charles H. Mims, MD	The Diagnostic Clinic of San Antonio			4647 Medical Drive	San Antonio, TX 78229
Peter V. Pickens, MD	Abington Hematology-Oncology Assoc		- Suite 112	1650 Huntingdon Pike	Meadowbrook, PA 19046
Eric P. Lester, MD	Lakeland Medical Center, St Joseph			1234 Napier Avenue	St Joseph, MI 49085
Hans Nevinny, MD	Cancer Treatment Center of Tulsa		- Suite 100	2408 East 81st Street	Tulsa, OK 74137-4210
Mark Woodson, MD	Hematology Oncology Consultants, Inc		- Suite 308, Christian NE Medical Bldg #2	11125 Dunn Road	St Louis, MO 63136
William R. Edwards, MD	The Cancer Center		- Rockford Medical	2350 North Rockton Avenue	Rockford, IL 61103

Trial 1053JIL/0030 ~ Replied to Request for Disclosure

NO FINANCIAL ARRANGEMENTS

Name	Facility	address 1	address 2	address 3	City, State, Zip
Juanito P. Singson, MD	Oncology Associates, S.C.		- Suite 105	3267 South 16th Street	Milwaukee, WI 53215
M. Roy Thomas, MD	Mid Dakota Clinic			401 North 9th Street	Bismarck, ND 58506-5510
Kelly Pendergrass, MD	Kansas City Internal Medicine		- Suite T 101	6420 Prospect Avenue	Kansas City, MO 64132
Barry Leinbersky, MD	Allegheny University Hospitals	Allegheny General	- South Tower, 7th Floor	320 East North Avenue	Pittsburgh, PA 15212
Jeffrey G. Schneider, MD	Winthrop University Hospital	Oncology/Hematology Division	222 Station Plaza North	Professional Bldg - Suite 300	Mincola, NY 11501
Harish K. Malhotra, MD, FACP	North Shore Hemato/Oncol Associates			235 North Belle Mead Road	East Setauket, NY 11733
William N. Harwin, MD	Florida Cancer Specialists			3840 Broadway	Fort Myers, FL 33901
Warren L. Woodard, MD	Blumenthal Cancer Center at	Carolinas Medical Center	- 3rd Floor	1000 Blythe Blvd	Charlotte, NC 28203
Steven Limentani, MD					
Alan P. Lyss, MD	Missouri Baptist Cancer Center			3015 North Ballas Road	St Louis, MO 63131
Robert O. Kerr, MD	Southwest Regional Cancer Center		- Suite B-1	711 West 38th Street	Austin, TX 78705
Gerald P. Miletto, MD	c/o Teresa Rehmeyer, RN	Baton Rouge General Regional Cancer Center		3600 Florida Boulevard	Baton Rouge, LA 70821-2511
Margaret A. Deutsch, MD	Raleigh Internal Medicine	Division of Cardinal Healthcare, PA	- Raleigh Medical Plaza	3320 Wake Forest Road	Raleigh, NC 27609
M. Francisco Gonzalez, MD	Univ of South Carolina School of Medicine	Division of Hematology/Oncology	- Suite 202	Seven Richland Medical Park	Columbia, SC 29203
Larry Schlabach, MD	University Oncology Associates		- Suite 5000	979 East Third Street	Chattanooga, TN 37403
Rayna Kneuper-Hall, MD	Medical University of South Carolina	Hollings Cancer Center	- Room 238	171 Ashley Avenue	Charleston, SC 29425

Trial 1053IL/0030 ~ Replied to Request for Disclosure

NO FINANCIAL ARRANGEMENTS

Name	Facility	address 1	address 2	address 3	City, State, Zip
John Root, MD	Kelsey-Seybold Foundation	Clinical Outcomes and Research	Suite 1700	6624 Fannin Street	Houston, TX 77030
David M. Owen, MD	Hattiesburg Clinic	Department of Oncology		415 South 28th Avenue	Hattiesburg, MS 39401
Abdul Zibdawi, MD	York County Hospital	Community Cancer Clinic		596 Davis Drive	Newmarket, Ontario L3Y 2P9 CA
John C. Michelson, MD	James Graham Brown Cancer Center	Division of Medical Oncology/Hematology	University of Louisville	529 South Jackson Street	Louisville, KY 40202
Steven Johnson, MD	Rapid City Regional Oncology Group		PO Box 6000	353 Fairmont Blvd	Rapid City, SD 57709
Kevin P. Mulvey, MD	Rutland Regional Medical Center	Green Mountain Oncology Group		160 Allen Street	Rutland, VT 05701
Thomas O'Rourke, MD	Grand Rapids Clinical Oncology Program		MC: 12	100 Michigan Avenue NE	Grand Rapids, MI 49503
Barry I. Cohen, MD	Greater Baltimore Medical Center	Cancer Center	Suite 205	6569 North Charles Street	Baltimore, MD 21204
Robert I. Van Amburg, MD			Suite 49 A-W	226 South Woods Mill Road	Chesterfield, MO 63017
Richard H. Woods, MD	Bend Memorial Clinic			1501 NE Medical Center Drive	Bend, OR 97701
Wayne Kelsner, MD	Redwood Regional Medical Group			3555 Round Barn Circle	Santa Rosa, CA 95403

**Trial 1033IL/0030 ~ No Response to Request for Disclosure as
of the date of this Report***

Name	Facility	address 1	address 2	address 3	City, State, Zip
Arnold I. Miller, DO	Regional Oncology/Hematology Assoc			802 West Oak Street	Kissimmee, FL 34741
Kala Seetharaman, MD	St Vincent's Hospital	Division of Hematology & Oncology		25 Winthrop Street	Worcester, MA 01604
Sandra Schnall, MD	Temple University Cancer Center			3322 North Broad Street	Philadelphia, PA 19140
Federico Sanchez, MD	c/o Christine Dufek	Clinical Research Management		11931 West Bluemound Road	Milwaukee, WI 53226-3999
Heather J. Alton, MD			Suite 203A	3920 South Eastern Avenue	Las Vegas, NV 89119
Deborah Lindquist, MD	Cancer Center of Northern Arizona		Suite 1	1329 North Beaver Street	Flagstaff, AZ 86001
Robert Chapman, MD	Henry Ford Hospital	Division of Hematology/Oncology K-13		2799 West Grant Blvd.	Detroit, MI 48202
Pradip Ganguly, MD	H Bliss Murphy Cancer Centre	Department of Radiation Oncology		300 Prince Philip Drive	St Johns, Newfoundland A1B 3V6 CA
Sean Latrelle	Hotel-Dieu de Montreal	Division of Hematology & Medical Oncology		3840 Rue St-Urbain	Montreal, Quebec H2W 1T8 CA
Susan Dent, MD	Northwestern Ontario Regional Cancer Cntr			290 Munro Street	Thunder Bay, Ontario P7A 7T1 CA
Andrew Arnold, MD	Hamilton Regional Cancer Center			699 Concession Street	Hamilton, Ontario L8V 5C2 CA
Paul Klimo, MD	Lions Gate Hospital	Oncology Clinic		231 East 15th Street	North Vancouver, British Columbia V7L 2L7 CA
Robyn Young, MD	Scott & White Memorial Hospital			2401 South 31st Street	Temple, TX 76508

*Indicates no sponsor payments identified by corporate accounting records.

**Trial 1053JIL/0030 ~ No Response to Request for Disclosure as
of the date of this Report***

Name	Facility	address 1	address 2	address 3	City, State, Zip
Marc Citron, MD	Long Island Jewish Medical Center	Medical Oncology Department	- AB-215	270-05 76th Avenue	New Hyde Park, NY 11040
Myo Thant, MD, MES	Hematology/Oncology Associates		- Suite 206	6830 Hospital Drive	Baltimore, MD 21237
Edward T. O'Brien, MD	The Regional Cancer Center			2500 West Twelfth Street	Erie, PA 16505
Rafal H. Ansari, MD	Memorial Hospital of South Bend	Oncology Research Office		615 North Michigan Street	South Bend, IN 46601-9986
Jamie E. Siegel, MD	Allegheny Univ Hospitals, MCP Division	Office of Hematology/Oncology		3300 Henry Avenue	Philadelphia, PA 19129
Lyndsay Harris, MD	Duke University Medical Center	Hematology and Medical Oncology	PO Box 3381 - Morris Building, Room 25128	Trent Drive	Durham, NC 27710
Frederick Ey, MD	HealthFirst Medical Group		- Research Office	265 North Broadway	Portland, OR 97227
Kathleen I. Pritchard, MD	Sunnybrook Health Science Center	Toronto-Bayview Regional Cancer Cntr		2075 Bayview Avenue	Toronto, Ontario M4N 3M5 CA
Kyran Bulger, MD	Wenatchee Valley Clinic	Clinical Research Department	PO Box 489	820 North Chelan Street	Wenatchee, WA 98801
Pamela Lepera, DO	East Carolina Univ School of Medicine	Department of Medicine	- 3E-127 Brody Building		Greenville, NC 27858
Charles R. Tweedy, MD	Amos Cancer Center		- Suite 320	2000 10th Avenue	Columbus, GA 31901
Kai-Yiu Yeung, MD	Oncology-Hematology Associates, PA	Heritage Medical Park	- Suite 201	8926 Woodyard Road	Clinton, MD 20735
Robert F. Granath, MD				980 Oak Street SE	Salem, OR 97301

*Indicates no sponsor payments identified by corporate accounting records.

10/07/99

4

**Trial 1033IL/0030 ~ No Response to Request for Disclosure as
of the date of this Report***

Name	Facility	address 1	address 2	address 3	City, State, Zip

APPEARS THIS WAY
ON ORIGINAL

Indicates no sponsor payments identified by corporate accounting records.

11/07/99

45

Trial 1033IL/0030 Sub-Investigators ~ Reply to Request for Disclosure

NO FINANCIAL ARRANGEMENTS

Name	address	address	address	address	city,state,zip	Co
Daniel J. Booser, MD	MD Anderson Cancer Cntr	Univ of Texas	Box 56	1515 Holcombe Blvd	Houston, TX 77030	
Frankie Holmes, MD	MD Anderson Cancer Cntr	Univ of Texas	Box 56	1515 Holcombe Blvd	Houston, TX 77030	
Gabriel N. Hortobagyi, MD	MD Anderson Cancer Cntr	Univ of Texas	Box 56	1515 Holcombe Blvd	Houston, TX 77030	
Nuhad Ibrahim, MD	MD Anderson Cancer Cntr	Univ of Texas	Box 56	1515 Holcombe Blvd	Houston, TX 77030	
Edgardo Rivera, MD	MD Anderson Cancer Cntr	Univ of Texas	Box 56	1515 Holcombe Blvd	Houston, TX 77030	
Richard Theriault, DO	MD Anderson Cancer Cntr	Univ of Texas	Box 56	1515 Holcombe Blvd	Houston, TX 77030	
Vicente Valero, MD	MD Anderson Cancer Cntr	Univ of Texas	Box 56	1515 Holcombe Blvd	Houston, TX 77030	
Ronald Wallers, MD *	MD Anderson Cancer Cntr	Univ of Texas	Box 56	1515 Holcombe Blvd	Houston, TX 77030	
James L. Lee Murray, MD	MD Anderson Cancer Cntr	Univ of Texas	Box 56	1515 Holcombe Blvd	Houston, TX 77030	
Robert Bast, MD	MD Anderson Cancer Cntr	Univ of Texas	Box 56	1515 Holcombe Blvd	Houston, TX 77030	
Andrzej Kudelka, MD	MD Anderson Cancer Cntr	Univ of Texas	Box 56	1515 Holcombe Blvd	Houston, TX 77030	
Marguerite Rosales, MD	MD Anderson Cancer Cntr	Univ of Texas	Box 56	1515 Holcombe Blvd	Houston, TX 77030	
Francisco Esteva, MD	MD Anderson Cancer Cntr	Univ of Texas	Box 56	1515 Holcombe Blvd	Houston, TX 77030	
Jorge G. Otoy, MD	Reg Oncology/Hematology Assoc	802 West Oak St			Kissimmee, FL 34741	
Barry S. Berman, MD	Reg Oncology/Hematology Assoc	802 West Oak St			Kissimmee, FL 34741	
M. Regina Flores, MD	Reg Oncology/Hematology Assoc	802 West Oak St			Kissimmee, FL 34741	

Trial 1033IL/0030 Sub-Investigators ~ Replieu to Request for Disclosure

NO FINANCIAL ARRANGEMENTS

Name	address	address	address	address	city,state,zip	Co
R.C. Brown, MD	INTEGRIS Oncology Services	Box 100 4210	3300 Northwest Exp		Oklahoma City, OK 73112-4481	
Brian V. Geister, MD	INTEGRIS Oncology Services	Box 100 4210	3300 Northwest Exp		Oklahoma City, OK 73112-4481	
James W. Hampton, MD	INTEGRIS Oncology Services	Box 100 4210	3300 Northwest Exp		Oklahoma City, OK 73112-4481	
Charles Hollen, MD	INTEGRIS Oncology Services	Box 100 4210	3300 Northwest Exp		Oklahoma City, OK 73112-4481	
Gregory A. Parker, MD	INTEGRIS Oncology Services	Box 100 4210	3300 Northwest Exp		Oklahoma City, OK 73112-4481	
Aleda Toma, MD	INTEGRIS Oncology Services	Box 100 4210	3300 Northwest Exp		Oklahoma City, OK 73112-4481	
Richard Bottomley, MD	INTEGRIS Oncology Services	Box 100 4210	3300 Northwest Exp		Oklahoma City, OK 73112-4481	
Khader Hussein, MD	INTEGRIS Oncology Services	Box 100 4210	3300 Northwest Exp		Oklahoma City, OK 73112-4481	
Kathy Dagg, MD	INTEGRIS Oncology Services	Box 100 4210	3300 Northwest Exp		Oklahoma City, OK 73112-4481	
Peter A. Kouides, MD	Rochester Gen Hosp	Dept of Medicine	1425 Portland Ave		Rochester, NY 14621-3001	
Jeanette L. Alavella, Pharm. D	Rochester Gen Hosp	Dept of Medicine	1425 Portland Ave		Rochester, NY 14621-3001	
K. Schwartz, MD	Michigan State Univ	Dept of Medicine	B-338 Clinical Cntr		East Lansing, MI 48824-1317	
D. Wong, MD	Michigan State Univ	Dept of Medicine	B-338 Clinical Cntr		East Lansing, MI 48824-1317	
Eldon Andersen, MD	Hema/Oncol, Kaiser Permanente	Central Interstate Med Office	1st Floor	3600 North Interstate Ave	Portland, OR 97227-1191	
Norman Bindorf, MD	Hema/Oncol, Kaiser Permanente	Central Interstate Med Office	1st Floor	3600 North Interstate Ave	Portland, OR 97227-1191	
Robert Bigler II, MD	Hema/Oncol, Kaiser Permanente	Central Interstate Med Office	1st Floor	3600 North Interstate Ave	Portland, OR 97227-1191	

Trial 1033IL/0030 Sub-Investigators ~ Replied to Request for Disclosure

NO FINANCIAL ARRANGEMENTS

Name	address	address	address	address	city,state,zip	Co
Mark U. Raick, MD	Hema/Oncol, Kaiser Permanente	Central Interstate Med Office	1st Floor	3600 North Interstate Ave	Portland, OR 97227-1191	
Joseph T. Leimert, MD	Hema/Oncol, Kaiser Permanente	Central Interstate Med Office	1st Floor	3600 North Interstate Ave	Portland, OR 97227-1191	
Gerard M. Segal, MD	Hema/Oncol, Kaiser Permanente	Central Interstate Med Office	1st Floor	3600 North Interstate Ave	Portland, OR 97227-1191	
Eber Camacho, MD	Desert Hosp	Comprehensive Cancer Cntr	Suite E 320	1180 North Indian Canyon Drive	Palm Springs, CA 92262	
Glenn Mills, MD	Louisiana State Univ Med Cntr	Dept of Medicine	PO Box 33932	1501 Kings Highway	Shreveport, LA 71130-3932	
Janardan D. Khandekar, MD	Evanston Northwestern Healthcare	Kellogg Cancer Care Cntr	2650 Ridge Ave		Evanston, IL 60201	
Douglas E. Merkel, MD	Evanston Northwestern Healthcare	Kellogg Cancer Care Cntr	2650 Ridge Ave		Evanston, IL 60201	
Daniel Shevlin, MD	Evanston Northwestern Healthcare	Kellogg Cancer Care Cntr	2650 Ridge Ave		Evanston, IL 60201	
Laurence Elias, MD	Univ of New Mexico	Cancer Res & Treatment Cntr	900 Camino de Salud, NE		Albuquerque, NM 87131	
John H. Saki, MD	Univ of New Mexico	Cancer Res & Treatment Cntr	900 Camino de Salud, NE		Albuquerque, NM 87131	
David R. Clarkson, MD	Providence Hosp	Suite A208	6701 Airport Blvd		Mobile, AL 36608	
Thaddeus A. Becker, MD	Providence Hosp	Suite A208	6701 Airport Blvd		Mobile, AL 36608	
Neel Hammond, MD	Billings InterHosp Oncology Project	Suite #2	1239 North 28th St		Billings, MT 59101	
Benjamin Marchello, MD	Billings InterHosp Oncology Project	Suite #2	1239 North 28th St		Billings, MT 59101	
Gerardo Midence, MD	Billings InterHosp Oncology Project	Suite #2	1239 North 28th St		Billings, MT 59101	

Trial 1033IL/0030 Sub-Investigators ~ Replied to Request for Disclosure

NO FINANCIAL ARRANGEMENTS

Name	address	address	address	address	city,state,zip	Co
Patrick Cobb, MD	Billings InterHosp Oncology Project	Suite #2	1239 North 28th St		Billings, MT 59101	
Frank Lamm, MD	Billings InterHosp Oncology Project	Suite #2	1239 North 28th St		Billings, MT 59101	
John Terry, MD	Billings InterHosp Oncology Project	Suite #2	1239 North 28th St		Billings, MT 59101	
Donald Twito, MD	Billings InterHosp Oncology Project	Suite #2	1239 North 28th St		Billings, MT 59101	
Roger Santala, MD	Billings InterHosp Oncology Project	Suite #2	1239 North 28th St		Billings, MT 59101	
Brock Whittenberger, MD	Billings InterHosp Oncology Project	Suite #2	1239 North 28th St		Billings, MT 59101	
Philip Bieman, MD	Univ of Nebraska Med Cntr	Dept of Hematology & Oncology	PO Box 983330	600 South 42nd St	Omaha, NE 68198-3330	
James Armitage, MD	Univ of Nebraska Med Cntr	Dept of Hematology & Oncology	PO Box 983330	600 South 42nd St	Omaha, NE 68198-3330	
Michael Bishop, MD	Univ of Nebraska Med Cntr	Dept of Hematology & Oncology	PO Box 983330	600 South 42nd St	Omaha, NE 68198-3330	
Julie Vose, MD	Univ of Nebraska Med Cntr	Dept of Hematology & Oncology	PO Box 983330	600 South 42nd St	Omaha, NE 68198-3330	
Anne Kessinger, MD	Univ of Nebraska Med Cntr	Dept of Hematology & Oncology	PO Box 983330	600 South 42nd St	Omaha, NE 68198-3330	
Michael Engleberg, MD	Cedars Sinai Comprehensive Cancer Cntr	8700 Beverly Blvd			Los Angeles, CA 90048	
Charles Forscher, MD	Cedars Sinai Comprehensive Cancer Cntr	8700 Beverly Blvd			Los Angeles, CA 90048	
Edward Wolin, MD	Cedars Sinai Comprehensive Cancer Cntr	8700 Beverly Blvd			Los Angeles, CA 90048	
Carlos Castillo, MD	Jacksonville Oncology Group	6629 Beach Blvd			Jacksonville, FL 32216-2816	
Walter W. Bate, MD	North Iowa Mercy Health Cntr	Mercy Cancer Cntr	1000 4th St SW		Mason City, IA 50401	

Trial 1033IL/0030 Sub-Investigators ~ Replied to Request for Disclosure

NO FINANCIAL ARRANGEMENTS

Name	address	address	address	address	city,state,zip	Co
Martha A. Ryan, MD	North Iowa Mercy Health Cntr	Mercy Cancer Cntr	1000 4th St SW		Mason City, IA 50401	
Timothy K. McKone, MD	North Iowa Mercy Health Cntr	Mercy Cancer Cntr	1000 4th St SW		Mason City, IA 50401	
Michael E. Klein, MD	Central PA Hematology & Med Oncol Assoc	50 North 12th St			Lemoyne, PA 17043	
John D. Conroy, Jr, DO	Central PA Hematology & Med Oncol Assoc	50 North 12th St			Lemoyne, PA 17043	
Alfred R. Leal, MD	Central PA Hematology & Med Oncol Assoc	50 North 12th St			Lemoyne, PA 17043	
Jennifer L. Cadiz, MD	Central PA Hematology & Med Oncol Assoc	50 North 12th St			Lemoyne, PA 17043	
Robert A. Gordon, MD	Central PA Hematology & Med Oncol Assoc	50 North 12th St			Lemoyne, PA 17043	
Roland R. Alexander, MD*	Central PA Hematology & Med Oncol Assoc	50 North 12th St			Lemoyne, PA 17043	
Dixie Lebo, RN *	Central PA Hematology & Med Oncol Assoc	50 North 12th St			Lemoyne, PA 17043	
James Rooney, MD	St Vincent's Hosp	Div of Hematology & Oncology	25 Winthrop St		Worcester, MA 01604	
Joseph Fontana, MD	Univ of Maryland Cancer Cntr	22 South Greene St			Baltimore, MD 21201	

Trial 1033IL/0030 Sub-Investigators ~ Replied to Request for Disclosure

NO FINANCIAL ARRANGEMENTS

Name	address	address	address	address	city,state,zip	Co
Christopher Benz, MD	UCSF Mount Zion Cancer Cntr	Breast Care Cntr	6th Floor	2356 Sutter St	San Francisco, CA 94115	
Charles Dollbaum, MD	UCSF Mount Zion Cancer Cntr	Breast Care Cntr	6th Floor	2356 Sutter St	San Francisco, CA 94115	
Nancy Valente, MD	UCSF Mount Zion Cancer Cntr	Breast Care Cntr	6th Floor	2356 Sutter St	San Francisco, CA 94115	
Manuel Martinez-Rio, MD	2400 North Univ Drive	Suite 200			Pembroke Pines, FL 33024	
Michael Greenhawt, MD	2400 North Univ Drive	Suite 200			Pembroke Pines, FL 33024	
Sarah T. Lincoln, MD	Rush-Presbyterian-St Lukes Med Cntr	Prof Bldg II, Suite 821	1725 West Harrison St		Chicago, IL 60612	
John Showel, MD	Rush-Presbyterian-St Lukes Med Cntr	Prof Bldg II, Suite 821	1725 West Harrison St		Chicago, IL 60612	
Philip Bonomi, MD	Rush-Presbyterian-St Lukes Med Cntr	Prof Bldg II, Suite 821	1725 West Harrison St		Chicago, IL 60612	
Parameswaran Venugopal, MD*	Rush-Presbyterian-St Lukes Med Cntr	Prof Bldg II, Suite 821	1725 West Harrison St		Chicago, IL 60612	
Samuel G. Taylor, MD	Rush-Presbyterian-St Lukes Med Cntr	Prof Bldg II, Suite 821	1725 West Harrison St		Chicago, IL 60612	
David Flinker, MD	Fox Chase Cancer Cntr at	Memorial Hosp of Burlington Co	4 Stokes	175 Madison Ave	Mt Holly, NJ 08060	
Alan S. Weinstein, MD	Fox Chase Cancer Cntr at	Memorial Hosp of Burlington Co	4 Stokes	175 Madison Ave	Mt Holly, NJ 08060	
Maurice J. Carroll, MD	Fox Chase Cancer Cntr at	Memorial Hosp of Burlington Co	4 Stokes	175 Madison Ave	Mt Holly, NJ 08060	
Eduardo Fernandez, MD*	Fox Chase Cancer Cntr at	Memorial Hosp of Burlington Co	4 Stokes	175 Madison Ave	Mt Holly, NJ 08060	
Arthur N. Kales, MD	Fairfax Prince William Hema/Oncol	Suite 230	3289 Woodburn Road		Annandale, VA 22003-1296	
Richard A. Binder, MD	Fairfax Prince William Hema/Oncol	Suite 230	3289 Woodburn Road		Annandale, VA 22003-1296	

Trial 1033IL/0030 Sub-Investigators ~ Replied to Request for Disclosure

NO FINANCIAL ARRANGEMENTS

Name	address	address	address	address	city,state,zip	Co
John A. Miller, MD	Fairfax Prince William Hema/Oncol	Suite 230	3289 Woodburn Road		Annandale, VA 22003-1296	
Roy A. Beveridge, MD	Fairfax Prince William Hema/Oncol	Suite 230	3289 Woodburn Road		Annandale, VA 22003-1296	
Daniel Katcher, MD	Fairfax Prince William Hema/Oncol	Suite 230	3289 Woodburn Road		Annandale, VA 22003-1296	
Winston M. Ueno, MD	Fairfax Prince William Hema/Oncol	Suite 230	3289 Woodburn Road		Annandale, VA 22003-1296	
Robert L. Reid, MD	Fairfax Prince William Hema/Oncol	Suite 230	3289 Woodburn Road		Annandale, VA 22003-1296	
Alan Rosenblum, MD	Santa Barbara Hema/Oncol Med Group, Inc	Cancer Foundation of Santa Barbara	300 West Pueblo St		Santa Barbara, CA 93105	
Julie Taguchi, MD	Santa Barbara Hema/Oncol Med Group, Inc	Cancer Foundation of Santa Barbara	300 West Pueblo St		Santa Barbara, CA 93105	
Thomas Woliver, MD	Santa Barbara Hema/Oncol Med Group, Inc	Cancer Foundation of Santa Barbara	300 West Pueblo St		Santa Barbara, CA 93105	
Wayne Kidder, MD	Santa Barbara Hema/Oncol Med Group, Inc	Cancer Foundation of Santa Barbara	300 West Pueblo St		Santa Barbara, CA 93105	
John Fiore, MD	Univ Hosp	Med Oncol HSC T-17, 080	SUNY at Stony Brook		Stony Brook, NY 11794-8174	
Stanley Ostrow, MD	Univ Hosp	Med Oncol HSC T-17, 080	SUNY at Stony Brook		Stony Brook, NY 11794-8174	
Malcolm Trimble, MD	Hema/Oncol Associates	Suite 201	1100 East Michigan Ave		Jackson, MI 49201	
James M. Epstein, MD	Missouri Baptist Cancer Cntr	3015 North Ballas Road			St Louis, MO 63131	

Trial 1033IL/0030 Sub-Investigators ~ Replied to Request for Disclosure

NO FINANCIAL ARRANGEMENTS

Name	address	address	address	address	city,state,zip	Co
Paul K. Schultz, MD	Missouri Baptist Cancer Cntr	3015 North Ballas Road			St Louis, MO 63131	
Deborah A. Weinski, MD	Missouri Baptist Cancer Cntr	3015 North Ballas Road			St Louis, MO 63131	

APPEARS THIS WAY
ON ORIGINAL

Trial J33IL/0030 Sub-Investigators ~ No Response to Request for Disclosure as of the Date of this Report*

Name	address	address	address	address	city.state.zip	Co
Zia Rahman, MD	MD Anderson Cancer Cntr	Univ of Texas	Box 56	1515 Holcombe Blvd	Houston, TX 77030	
Marguerite Rosales, MD	MD Anderson Cancer Cntr	Univ of Texas	Box 56	1515 Holcombe Blvd	Houston, TX 77030	
Sn Rosenthal, MD *	Rochester Gen Hosp	Dept of Medicine	1425 Portland Ave		Rochester, NY 14621-3001	
D. MacDonald, MD	Michigan State Univ	Dept of Medicine	B-338 Clinical Cntr		East Lansing, MI 48824-1317	
L. Wulfekuhler, MD	Michigan State Univ	Dept of Medicine	B-338 Clinical Cntr		East Lansing, MI 48824-1317	
P. Gulick, DO	Michigan State Univ	Dept of Medicine	B-338 Clinical Cntr		East Lansing, MI 48824-1317	
M. DeMatila, DO	Michigan State Univ	Dept of Medicine	B-338 Clinical Cntr		East Lansing, MI 48824-1317	
J. Bartnik, MD	Michigan State Univ	Dept of Medicine	B-338 Clinical Cntr		East Lansing, MI 48824-1317	
D. Arnold, MD	Michigan State Univ	Dept of Medicine	B-338 Clinical Cntr		East Lansing, MI 48824-1317	
A. Scholnik, MD	Michigan State Univ	Dept of Medicine	B-338 Clinical Cntr		East Lansing, MI 48824-1317	
M. Aurora, MD	Michigan State Univ	Dept of Medicine	B-338 Clinical Cntr		East Lansing, MI 48824-1317	
J. Letzer, DO	Michigan State Univ	Dept of Medicine	B-338 Clinical Cntr		East Lansing, MI 48824-1317	
E. Layhe, DO	Michigan State Univ	Dept of Medicine	B-338 Clinical Cntr		East Lansing, MI 48824-1317	
W. Kamada, MD	Michigan State Univ	Dept of Medicine	B-338 Clinical Cntr		East Lansing, MI 48824-1317	
E. Balcueva, MD	Michigan State Univ	Dept of Medicine	B-338 Clinical Cntr		East Lansing, MI 48824-1317	
D. Cook, MD	Michigan State Univ	Dept of Medicine	B-338 Clinical Cntr		East Lansing, MI 48824-1317	

*Indicates no sponsor payments identified by corporate accounting records.

9/27/99

LS

Trial 1u33IL/0030 Sub-Investigators ~ No Response to Request for Disclosure as of the Date of this Report*

Name	address	address	address	address	city.state.zip	Co
J. Abramson, MD	Michigan State Univ	Dept of Medicine	B-338 Clinical Cntr		East Lansing, MI 48824-1317	
K. Stoutenborough, MD	Michigan State Univ	Dept of Medicine	B-338 Clinical Cntr		East Lansing, MI 48824-1317	
T. Singh, MD	Michigan State Univ	Dept of Medicine	B-338 Clinical Cntr		East Lansing, MI 48824-1317	
Gary Doolittle, MD	Univ of Kansas Med Cntr	Div of Clinical Oncology	3901 Rainbow Blvd.		Kansas City, KS 66160-7353	
Richard McKNtrick, MD	Univ of Kansas Med Cntr	Div of Clinical Oncology	3901 Rainbow Blvd.		Kansas City, KS 66160-7353	
Raj Sadasivan, MD	Univ of Kansas Med Cntr	Div of Clinical Oncology	3901 Rainbow Blvd.		Kansas City, KS 66160-7353	
Ronald Stephens, MD	Univ of Kansas Med Cntr	Div of Clinical Oncology	3901 Rainbow Blvd.		Kansas City, KS 66160-7353	
Sarah Taylor, MD	Univ of Kansas Med Cntr	Div of Clinical Oncology	3901 Rainbow Blvd.		Kansas City, KS 66160-7353	
Stan Vogel, MD	Univ of Kansas Med Cntr	Div of Clinical Oncology	3901 Rainbow Blvd.		Kansas City, KS 66160-7353	
Stephen Williamson, MD	Univ of Kansas Med Cntr	Div of Clinical Oncology	3901 Rainbow Blvd.		Kansas City, KS 66160-7353	
Stephen Chandler, MD	Hema/Oncol, Kaiser Permanente	Central Interstate Med Office	1st Floor	3600 North Interstate Ave	Portland, OR 97227-1191	
Paul Wallace, MD *	Hema/Oncol, Kaiser Permanente	Central Interstate Med Office	1st Floor	3600 North Interstate Ave	Portland, OR 97227-1191	
Jonathan Glass, MD	Louisiana State Univ Med Cntr	Dept of Medicine	PO Box 33932	1501 Kings Highway	Shreveport, LA 71130-3932	
Robert Nickelson, MD	Louisiana State Univ Med Cntr	Dept of Medicine	PO Box 33932	1501 Kings Highway	Shreveport, LA 71130-3932	
Laura Campbell, MD	Louisiana State Univ Med Cntr	Dept of Medicine	PO Box 33932	1501 Kings Highway	Shreveport, LA 71130-3932	
Daniel Shevlin, MD	Evanston Northwestern Healthcare	Kellogg Cancer Care Cntr	2650 Ridge Ave		Evanston, IL 60201	

*Indicates no sponsor payments identified by corporate accounting records.

9/27/99

SS

Trial 1033IL/0030 Sub-Investigators ~ No Response to Request for Disclosure as of the Date of this Report*

Name	address	address	address	address	city.state.zip	Co
Laurence Elias, MD	Univ of New Mexico	Cancer Res & Treatment Cntr	900 Camino de Salud, NE		Albuquerque, NM 87131	
Kenneth Friedman, MD	Univ of New Mexico	Cancer Res & Treatment Cntr	900 Camino de Salud, NE		Albuquerque, NM 87131	
James Liebmann, MD	Univ of New Mexico	Cancer Res & Treatment Cntr	900 Camino de Salud, NE		Albuquerque, NM 87131	
C. Richard Lyons, MD	Univ of New Mexico	Cancer Res & Treatment Cntr	900 Camino de Salud, NE		Albuquerque, NM 87131	
Daniel A. Polansky, MD	Providence Hosp	Suite A208	6701 Airport Blvd		Mobile, AL 36608	
Michael Lory Campbell, MD *	Providence Hosp	Suite A208	6701 Airport Blvd		Mobile, AL 36608	
Fred Deigert, MD	Billings InterHosp Oncology Project	Suite #2	1239 North 28th St		Billings, MT 59101	
Cherie Hayostek, MD	Billings InterHosp Oncology Project	Suite #2	1239 North 28th St		Billings, MT 59101	
Mark Dion, MD	Billings InterHosp Oncology Project	Suite #2	1239 North 28th St		Billings, MT 59101	
Judy Schmidt, MD	Billings InterHosp Oncology Project	Suite #2	1239 North 28th St		Billings, MT 59101	
Annie Castillo, MD	Billings InterHosp Oncology Project	Suite #2	1239 North 28th St		Billings, MT 59101	
James Hueftle, MD	Billings InterHosp Oncology Project	Suite #2	1239 North 28th St		Billings, MT 59101	
Eugene Hughes Jr, MD	Billings InterHosp Oncology Project	Suite #2	1239 North 28th St		Billings, MT 59101	
Simeon Conrill, MD	Billings InterHosp Oncology Project	Suite #2	1239 North 28th St		Billings, MT 59101	
Mark R. Hancock, MD	Billings InterHosp Oncology Project	Suite #2	1239 North 28th St		Billings, MT 59101	
Siefano Tarantolo, MD	Univ of Nebraska Med Cntr	Dept of Hematology & Oncology	PO Box 983330	600 South 42nd St	Omaha, NE 68198-3330	

*Indicates no sponsor payments identified by corporate accounting records.

9/27/99

95

Trial 1033IL/0030 Sub-Investigators ~ No Response to Request for Disclosure as of the Date of this Report*

Name	address	address	address	address	city.state.zip	Co
Margaret Tempero, MD	Univ of Nebraska Med Cntr	Dept of Hematology & Oncology	PO Box 983330	600 South 42nd St	Omaha, NE 68198-3330	
John Foley, MD	Univ of Nebraska Med Cntr	Dept of Hematology & Oncology	PO Box 983330	600 South 42nd St	Omaha, NE 68198-3330	
William Audeh, MD,	Cedars Sinai Comprehensive Cancer Cntr	8700 Beverly Blvd			Los Angeles, CA 90048	
Francis Giles, MD *	Cedars Sinai Comprehensive Cancer Cntr	8700 Beverly Blvd			Los Angeles, CA 90048	
Gerald Rosen, MD *	Cedars Sinai Comprehensive Cancer Cntr	8700 Beverly Blvd			Los Angeles, CA 90048	
Christopher Seidler, MD	St Vincent's Hosp	Div of Hematology & Oncology	25 Winthrop St		Worcester, MA 01604	
Herbert Dean, MD	St Vincent's Hosp	Div of Hematology & Oncology	25 Winthrop St		Worcester, MA 01604	
Patty Arsenault, RN	St Vincent's Hosp	Div of Hematology & Oncology	25 Winthrop St		Worcester, MA 01604	
Kathy Rooney, PA	St Vincent's Hosp	Div of Hematology & Oncology	25 Winthrop St		Worcester, MA 01604	
Maggie Charpentier, PharmD	St Vincent's Hosp	Div of Hematology & Oncology	25 Winthrop St		Worcester, MA 01604	
Dominique Lemieux, MS	St Vincent's Hosp	Div of Hematology & Oncology	25 Winthrop St		Worcester, MA 01604	
Garrett Smith, MD	UCSF Mount Zion Cancer Cntr	Breast Care Cntr	6th Floor	2356 Sutter St	San Francisco, CA 94115	
I. Craig Henderson, MD	UCSF Mount Zion Cancer Cntr	Breast Care Cntr	6th Floor	2356 Sutter St	San Francisco, CA 94115	
Mohammad Jahanzab, MD	2400 North Univ Drive	Suite 200			Pembroke Pines, FL 33024	
Peter Radice, MD	2400 North Univ Drive	Suite 200			Pembroke Pines, FL 33024	
Alan Koletsky, MD	2400 North Univ Drive	Suite 200			Pembroke Pines, FL 33024	

*Indicates no sponsor payments identified by corporate accounting records.

9/27/99

25

Trial 1033IL/0030 Sub-Investigators ~ No Response to Request for Disclosure as of the Date of this Report*

Name	address	address	address	address	city.state.zip	Co
Eduardo Gomez, MD	2400 North Univ Drive	Suite 200			Pembroke Pines, FL 33024	
Arnold Berliner, MD	2400 North Univ Drive	Suite 200			Pembroke Pines, FL 33024	
Elena Kruglyak, MD	2400 North Univ Drive	Suite 200			Pembroke Pines, FL 33024	
Ramon Rodriguez-Torres, MD	2400 North Univ Drive	Suite 200			Pembroke Pines, FL 33024	
Carlos Gulda, MD *	2400 North Univ Drive	Suite 200			Pembroke Pines, FL 33024	
Marvin Diaz-Lacayo, MD *	2400 North Univ Drive	Suite 200			Pembroke Pines, FL 33024	
Harvey Hotchner, MD *	2400 North Univ Drive	Suite 200			Pembroke Pines, FL 33024	
Stephen Grabelsky, MD*	2400 North Univ Drive	Suite 200			Pembroke Pines, FL 33024	
Jules E. Harris, MD	Rush-Presbyterian-St Lukes Med Cntr	Prof Bldg II, Suite 821	1725 West Harrison St		Chicago, IL 60612	
Sn LaFollette, MD	Rush-Presbyterian-St Lukes Med Cntr	Prof Bldg II, Suite 821	1725 West Harrison St		Chicago, IL 60612	
Melody Cobleigh, MD	Rush-Presbyterian-St Lukes Med Cntr	Prof Bldg II, Suite 821	1725 West Harrison St		Chicago, IL 60612	
David Lyter, MD	Rush-Presbyterian-St Lukes Med Cntr	Prof Bldg II, Suite 821	1725 West Harrison St		Chicago, IL 60612	
Sabel Skdikul, MD*	Rush-Presbyterian-St Lukes Med Cntr	Prof Bldg II, Suite 821	1725 West Harrison St		Chicago, IL 60612	
Gurdeep S. Sethi, MD	Rush-Presbyterian-St Lukes Med Cntr	Prof Bldg II, Suite 821	1725 West Harrison St		Chicago, IL 60612	
Erol Yorulmazoglu, MD	Rush-Presbyterian-St Lukes Med Cntr	Prof Bldg II, Suite 821	1725 West Harrison St		Chicago, IL 60612	
Stanislav Nabrinsky, MD	Rush-Presbyterian-St Lukes Med Cntr	Prof Bldg II, Suite 821	1725 West Harrison St		Chicago, IL 60612	

*Indicates no sponsor payments identified by corporate accounting records.

9/27/19

58

Trial 1033IL/0030 Sub-Investigators ~ No Response to Request for Disclosure as of the Date of this Report*

Name	address	address	address	address	city.state.zip	Co
Homayoun Shahidi, MD	Rush-Presbyterian-St Lukes Med Cntr	Prof Bldg II, Suite 821	1725 West Harrison St		Chicago, IL 60612	
Gregory J. Oriolf, MD	Fairfax Prince William Hema/Oncol	Suite 230	3289 Woodburn Road		Annandale, VA 22003-1296	
Robert J. Meister, MD	Fairfax Prince William Hema/Oncol	Suite 230	3289 Woodburn Road		Annandale, VA 22003-1296	
Mary J. Wilkinson, MD	Fairfax Prince William Hema/Oncol	Suite 230	3289 Woodburn Road		Annandale, VA 22003-1296	
Thomas P. Butler, MD	Fairfax Prince William Hema/Oncol	Suite 230	3289 Woodburn Road		Annandale, VA 22003-1296	
Patrick John Byrne, MD	Fairfax Prince William Hema/Oncol	Suite 230	3289 Woodburn Road		Annandale, VA 22003-1296	
Neeta Ahuja, MD	Fairfax Prince William Hema/Oncol	Suite 230	3289 Woodburn Road		Annandale, VA 22003-1296	
L.F. Smith, Jr, MD	Fairfax Prince William Hema/Oncol	Suite 230	3289 Woodburn Road		Annandale, VA 22003-1296	
Kenneth Koltz, MD	Fairfax Prince William Hema/Oncol	Suite 230	3289 Woodburn Road		Annandale, VA 22003-1296	
Peter Francis, MD	Fairfax Prince William Hema/Oncol	Suite 230	3289 Woodburn Road		Annandale, VA 22003-1296	
John M. Felger, MD	Fairfax Prince William Hema/Oncol	Suite 230	3289 Woodburn Road		Annandale, VA 22003-1296	
Robert F. Dobrzynski, MD	Fairfax Prince William Hema/Oncol	Suite 230	3289 Woodburn Road		Annandale, VA 22003-1296	
David M. Dunning, MD	Fairfax Prince William Hema/Oncol	Suite 230	3289 Woodburn Road		Annandale, VA 22003-1296	
David M. Heyer, MD	Fairfax Prince William Hema/Oncol	Suite 230	3289 Woodburn Road		Annandale, VA 22003-1296	
Anthony J. Felice, MD	Fairfax Prince William Hema/Oncol	Suite 230	3289 Woodburn Road		Annandale, VA 22003-1296	
Patricia Amelia Rodriguez, MD	Fairfax Prince William Hema/Oncol	Suite 230	3289 Woodburn Road		Annandale, VA 22003-1296	

*Indicates no sponsor payments identified by corporate accounting records.

9/27/99

5

Trial 1033IL/0030 Sub-Investigators ~ No Response to Request for Disclosure as of the Date of this Report*

Name	address	address	address	address	city.state.zip	Co
Mark Abate, MD	Santa Barbara Hema/Oncol Med Group, Inc	Cancer Foundation of Santa Barbara	300 West Pueblo St		Santa Barbara, CA 93105	
Martin Walker, MD	Santa Barbara Hema/Oncol Med Group, Inc	Cancer Foundation of Santa Barbara	300 West Pueblo St		Santa Barbara, CA 93105	
Lee Thompson, BS	Santa Barbara Hema/Oncol Med Group, Inc	Cancer Foundation of Santa Barbara	300 West Pueblo St		Santa Barbara, CA 93105	
Margaret Ray, MD	Santa Barbara Hema/Oncol Med Group, Inc	Cancer Foundation of Santa Barbara	300 West Pueblo St		Santa Barbara, CA 93105	
Thomas Lossing, MD	Santa Barbara Hema/Oncol Med Group, Inc	Cancer Foundation of Santa Barbara	300 West Pueblo St		Santa Barbara, CA 93105	
Steve Cooley, PharmD	Santa Barbara Hema/Oncol Med Group, Inc	Cancer Foundation of Santa Barbara	300 West Pueblo St		Santa Barbara, CA 93105	
Steven Sugarman, MD	Univ Hosp	Med Oncol HSC T-17, 080	SUNY at Stony Brook		Stoney Brook, NY 11794-8174	
Michael Viola, MD	Univ Hosp	Med Oncol HSC T-17, 080	SUNY at Stony Brook		Stoney Brook, NY 11794-8174	
William LIPera, MD	Univ Hosp	Med Oncol HSC T-17, 080	SUNY at Stony Brook		Stoney Brook, NY 11794-8174	
John Axelton, MD	Hema/Oncol Associates	Suite 201	1100 East Michigan Ave		Jackson, MI 49201	
Marion Grace Jordison-Boxer, MD	Hema/Oncol Associates	Suite 201	1100 East Michigan Ave		Jackson, MI 49201	
JoAnn S. Hirth, MD	Hema/Oncol Associates	Suite 201	1100 East Michigan Ave		Jackson, MI 49201	

*Indicates no sponsor payments identified by corporate accounting records.

9/27/99

8

Trial 1033IL/0030 Sub-Investigators ~ No Response to Request for Disclosure as of the Date of this Report*

Name	address	address	address	address	city.state.zip	Co
Peter Radice, MD	Comprehensive Cancer Cntr	21020 State Road 7			Boca Raton, FL 33428	
Mohammad Jahanzeb, MD	Comprehensive Cancer Cntr	21020 State Road 7			Boca Raton, FL 33428	
Vivek Samotra, MD	Comprehensive Cancer Cntr	21020 State Road 7			Boca Raton, FL 33428	
Victor Koo, MD *	Comprehensive Cancer Cntr	21020 State Road 7			Boca Raton, FL 33428	
Stephen Grablesky, MD *	Comprehensive Cancer Cntr	21020 State Road 7			Boca Raton, FL 33428	
Edem S. Agamah, MD	Memorial Med Cntr	Reg Cancer Cntr	701 North First St		Springfield, IL 62781	
Charles Wabner, MD	Memorial Med Cntr	Reg Cancer Cntr	701 North First St		Springfield, IL 62781	
Mary E. Bretscher, MD	Memorial Med Cntr	Reg Cancer Cntr	701 North First St		Springfield, IL 62781	
Edward L. Braud, MD	Memorial Med Cntr	Reg Cancer Cntr	701 North First St		Springfield, IL 62781	
Oswaldo Wesly, MD	Memorial Med Cntr	Reg Cancer Cntr	701 North First St		Springfield, IL 62781	
Leonard Glannone, MD	Memorial Med Cntr	Reg Cancer Cntr	701 North First St		Springfield, IL 62781	
Frances M. Matthews, MD	Memorial Med Cntr	Reg Cancer Cntr	701 North First St		Springfield, IL 62781	
Victor Lanzotti, MD	Memorial Med Cntr	Reg Cancer Cntr	701 North First St		Springfield, IL 62781	
Taril K. Banerjee, MD	Marshfield Clinic	3A Oncology	1000 North Oak Ave		Marshfield, WI 54449	
B. Danielle Bol de Greve, MD	Marshfield Clinic	3A Oncology	1000 North Oak Ave		Marshfield, WI 54449	
Lawrence H. Clouse, MD	Marshfield Clinic	3A Oncology	1000 North Oak Ave		Marshfield, WI 54449	

*Indicates no sponsor payments identified by corporate accounting records.

9/27/11

19

Trial 1033IL/0030 Sub-Investigators ~ No Response to Request for Disclosure as of the Date of this Report*

Name	address	address	address	address	city.state.zip	Co
Leland D. Crandall, MD	Marshfield Clinic	3A Oncology	1000 North Oak Ave		Marshfield, WI 54449	
William R. Friedenber, MD	Marshfield Clinic	3A Oncology	1000 North Oak Ave		Marshfield, WI 54449	
William G. Hocking, MD	Marshfield Clinic	3A Oncology	1000 North Oak Ave		Marshfield, WI 54449	
Y. Gregory Lin, MD	Marshfield Clinic	3A Oncology	1000 North Oak Ave		Marshfield, WI 54449	
Joseph J. Mazza, MD	Marshfield Clinic	3A Oncology	1000 North Oak Ave		Marshfield, WI 54449	
Richard J. Mercler, MD	Marshfield Clinic	3A Oncology	1000 North Oak Ave		Marshfield, WI 54449	
Douglas J. Reding, MD	Marshfield Clinic	3A Oncology	1000 North Oak Ave		Marshfield, WI 54449	
Daniel A. Rushing, MD	Marshfield Clinic	3A Oncology	1000 North Oak Ave		Marshfield, WI 54449	
Lee L. Schloesser, MD *	Marshfield Clinic	3A Oncology	1000 North Oak Ave		Marshfield, WI 54449	
Matthias Weiss, MD	Marshfield Clinic	3A Oncology	1000 North Oak Ave		Marshfield, WI 54449	
Roy Ambinder, MD	Florida Hosp	Suite 289	2501 North Orange Ave		Orlando, FL 32804	
Robert Reynolds, MD	Florida Hosp	Suite 289	2501 North Orange Ave		Orlando, FL 32804	
Philip Dunn, MD	Florida Hosp	Suite 289	2501 North Orange Ave		Orlando, FL 32804	
Ralph Gousse, MD	Florida Hosp	Suite 289	2501 North Orange Ave		Orlando, FL 32804	
David Robinson, MD	Florida Hosp	Suite 289	2501 North Orange Ave		Orlando, FL 32804	
Leo Zehngel, MD	Florida Hosp	Suite 289	2501 North Orange Ave		Orlando, FL 32804	

*Indicates no sponsor payments identified by corporate accounting records.

4/27/99

29

Trial 1033IL/0030 Sub-Investigators ~ No Response to Request for Disclosure as of the Date of this Report*

Name	address	address	address	address	city.state.zip	Co
Raul Castillo Gammill, MD	Florida Hosp	Suite 289	2501 North Orange Ave		Orlando, FL 32804	
David Smith, MD	Florida Hosp	Suite 289	2501 North Orange Ave		Orlando, FL 32804	
David Moltrop	Florida Hosp	Suite 289	2501 North Orange Ave		Orlando, FL 32804	
Laura Brinz, MD	Professional Med Corporation	Suite One	3939 Houma Blvd		Metairie, LA 70006	
Rita Axelrod, MD	Temple Univ Cancer Cntr	3322 North Broad St			Philadelphia, PA 19140	
John Macdonald, MD	Temple Univ Cancer Cntr	3322 North Broad St			Philadelphia, PA 19140	
Lance Leopold, MD	Temple Univ Cancer Cntr	3322 North Broad St			Philadelphia, PA 19140	
Pamela Lepra, DO	Temple Univ Cancer Cntr	3322 North Broad St			Philadelphia, PA 19140	
Marjorie A. Vukelich, MD	Clinical Res Management	11931 West Bluemound Road			Milwaukee, WI 53226-3999	
Arnold Wax, MD	Suite 203A	3920 South Eastern Ave			Las Vegas, NV 89119	
Isadore Brodsky, MD	Allegheny Univ of the Health Sciences	Hahnemann Divison	Mail Stop 412	Broad and Vine Sts	Philadelphia, PA 19102-1192	
James Conroy, DO	Allegheny Univ of the Health Sciences	Hahnemann Divison	Mail Stop 412	Broad and Vine Sts	Philadelphia, PA 19102-1192	
Phyllis Sabol, MD	Allegheny Univ of the Health Sciences	Hahnemann Divison	Mail Stop 412	Broad and Vine Sts	Philadelphia, PA 19102-1192	
Michael Styler, MD	Allegheny Univ of the Health Sciences	Hahnemann Divison	Mail Stop 412	Broad and Vine Sts	Philadelphia, PA 19102-1192	
David Topolsky, MD	Allegheny Univ of the Health Sciences	Hahnemann Divison	Mail Stop 412	Broad and Vine Sts	Philadelphia, PA 19102-1192	
Albert Ebenezzer, MD	Knoxville Hema/Oncol Assoc	Suite C	1114 Weisgarber Road		Knoxville, TN 37909	

*Indicates no sponsor payments identified by corporate accounting records.

0/27/11



Trial 1033IL/0030 Sub-Investigators ~ No Response to Request for Disclosure as of the Date of this Report*

Name	address	address	address	address	city.state.zip	Co
Peter Carter, MD	Knoxville Hema/Oncol Assoc	Suite C	1114 Weisgarber Road		Knoxville, TN 37909	
Jerry Foster, MD	Knoxville Hema/Oncol Assoc	Suite C	1114 Weisgarber Road		Knoxville, TN 37909	
Paul R. Kuefler, MD	Cancer Cntr of Northern Arizona	Suite 1	1329 North Beaver St		Flagstaff, AZ 86001	
David S. Mendelson, MD	Palo Verde Hema/Oncol Ltd	Suite 106	5601 West Egle		Glendale, AZ 85014	
Ellen J. Gustafson, MD	Palo Verde Hema/Oncol Ltd	Suite 106	5601 West Egle		Glendale, AZ 85014	
Joseph R. Volk, MD	Palo Verde Hema/Oncol Ltd	Suite 106	5601 West Egle		Glendale, AZ 85014	
Martin B. Langford, MD	Palo Verde Hema/Oncol Ltd	Suite 106	5601 West Egle		Glendale, AZ 85014	
Thomas Doyle, MD	Henry Ford Hosp	Div of Hema/Oncol K-13	2799 West Grant Blvd.		Detroit, MI 48202	
Joseph Anderson, MD	Henry Ford Hosp	Div of Hema/Oncol K-13	2799 West Grant Blvd.		Detroit, MI 48202	
Leslie Bricker, MD	Henry Ford Hosp	Div of Hema/Oncol K-13	2799 West Grant Blvd.		Detroit, MI 48202	
Nalini Janakiraman, MD	Henry Ford Hosp	Div of Hema/Oncol K-13	2799 West Grant Blvd.		Detroit, MI 48202	
Carolyn Schmidt, RN, MS	Henry Ford Hosp	Div of Hema/Oncol K-13	2799 West Grant Blvd.		Detroit, MI 48202	
Sheela Tejwani, MD	Henry Ford Hosp	Div of Hema/Oncol K-13	2799 West Grant Blvd.		Detroit, MI 48202	
Bennett Yu, MD	Henry Ford Hosp	Div of Hema/Oncol K-13	2799 West Grant Blvd.		Detroit, MI 48202	
Jason Stern, DO *	Henry Ford Hosp	Div of Hema/Oncol K-13	2799 West Grant Blvd.		Detroit, MI 48202	
Ira Wolner, MD	Henry Ford Hosp	Div of Hema/Oncol K-13	2799 West Grant Blvd.		Detroit, MI 48202	

*Indicates no sponsor payments identified by corporate accounting records.

Trial 1033IL/0030 Sub-Investigators ~ No Response to Request for Disclosure as of the Date of this Report*

Name	address	address	address	address	city.state.zip	Co
David Urbanski, MD *	Henry Ford Hosp	Div of Hema/Oncol K-13	2799 West Grant Blvd.		Detroit, MI 48202	
Nabeel Rajeh, MD	Henry Ford Hosp	Div of Hema/Oncol K-13	2799 West Grant Blvd.		Detroit, MI 48202	
Jule Kish, MD	Henry Ford Hosp	Div of Hema/Oncol K-13	2799 West Grant Blvd.		Detroit, MI 48202	
Bernd Barthel, MD	Henry Ford Hosp	Div of Hema/Oncol K-13	2799 West Grant Blvd.		Detroit, MI 48202	
Robert O' Bryan, MD	Henry Ford Hosp	Div of Hema/Oncol K-13	2799 West Grant Blvd.		Detroit, MI 48202	
Neeraj Sharma, MD*	Henry Ford Hosp	Div of Hema/Oncol K-13	2799 West Grant Blvd.		Detroit, MI 48202	
Sameera Khan, MD *	Henry Ford Hosp	Div of Hema/Oncol K-13	2799 West Grant Blvd.		Detroit, MI 48202	
Michael Stoltenberg, MD	Henry Ford Hosp	Div of Hema/Oncol K-13	2799 West Grant Blvd.		Detroit, MI 48202	
Warren Wong, MD	Henry Ford Hosp	Div of Hema/Oncol K-13	2799 West Grant Blvd.		Detroit, MI 48202	
Seraphim Pallas, MD	Henry Ford Hosp	Div of Hema/Oncol K-13	2799 West Grant Blvd.		Detroit, MI 48202	
Kim Hon Yee, MD	Henry Ford Hosp	Div of Hema/Oncol K-13	2799 West Grant Blvd.		Detroit, MI 48202	
Thomas W. Mehlman, MD	Lancaster Cancer Cntr Ltd	333 North Arch St			Lancaster, PA 17603	
Joan D. Kane, MD	Lancaster Cancer Cntr Ltd	333 North Arch St			Lancaster, PA 17603	
Muhyi Al-Sarraf, MD	Providence Hosp	3rd Floor	22301 Foster Winter Drive		Southfield, MI 48075	
Anibal Drelichman, MD	Providence Hosp	3rd Floor	22301 Foster Winter Drive		Southfield, MI 48075	
Howard R. Terebelo, DO	Providence Hosp	3rd Floor	22301 Foster Winter Drive		Southfield, MI 48075	

*Indicates no sponsor payments identified by corporate accounting records.

9/27/99

8

Trial 10331L/0030 Sub-Investigators ~ No Response to Request for Disclosure as of the Date of this Report*

Name	address	address	address	address	city.state.zip	Co
Jack Goldberg, MD	Cooper Hosp	Univ Med Cntr	Suite 220	3 Cooper Plaza	Camden, NJ 08103	
Ann Berger, MD	Cooper Hosp	Univ Med Cntr	Suite 220	3 Cooper Plaza	Camden, NJ 08103	
Linda Devereux, MD	Cooper Hosp	Univ Med Cntr	Suite 220	3 Cooper Plaza	Camden, NJ 08103	
Jeffery Gryn, MD	Cooper Hosp	Univ Med Cntr	Suite 220	3 Cooper Plaza	Camden, NJ 08103	
Mohammed Muslim, MD	Cooper Hosp	Univ Med Cntr	Suite 220	3 Cooper Plaza	Camden, NJ 08103	
Gamil Hannah, MD	Cooper Hosp	Univ Med Cntr	Suite 220	3 Cooper Plaza	Camden, NJ 08103	
Alex Hageboutros, MD *	Cooper Hosp	Univ Med Cntr	Suite 220	3 Cooper Plaza	Camden, NJ 08103	
Guillermo Rodriguez, MD	Oncology Care Cntr	4000 North Illinois			Belleville, IL 62226	
Jeffrey Kirshner, MD	Hematology & Oncology Associates	Suite 400	1000 East Genesse St		Syracuse, NY 13210	
John Guilo, MD	Hematology & Oncology Associates	Suite 400	1000 East Genesse St		Syracuse, NY 13210	
David Churchill, MD	Hematology & Oncology Associates	Suite 400	1000 East Genesse St		Syracuse, NY 13210	
Thomas Maher, MD	Hematology & Oncology Associates	Suite 400	1000 East Genesse St		Syracuse, NY 13210	
Anthony Scatzo, MD	Hematology & Oncology Associates	Suite 400	1000 East Genesse St		Syracuse, NY 13210	
Sario DiFino, MD	Hematology & Oncology Associates	Suite 400	1000 East Genesse St		Syracuse, NY 13210	
Jeffrey D. Isaacs, MD	Hematology Associates Ltd	Suite #501	3411 North 5th Ave		Phoenix, AZ 85013-3897	
Larry Hecker, MD	Hematology Associates Ltd	Suite #501	3411 North 5th Ave		Phoenix, AZ 85013-3897	

*Indicates no sponsor payments identified by corporate accounting records.

9/27/99

8

Trial 1033IL/0030 Sub-Investigators ~ No Response to Request for Disclosure as of the Date of this Report*

Name	address	address	address	address	city.state.zip	Co
P. Philip Scheerer, MD	Hematology Associates Ltd	Suite #501	3411 North 5th Ave		Phoenix, AZ 85013-3897	
Christopher J. Wakem, MD	Hema/Oncol	Suite 1A	55 Meriden Ave		Southington, CT 06489	
Barbara Fallon, MD,	Hema/Oncol	Suite 1A	55 Meriden Ave		Southington, CT 06489	
William H. Pogue, MD	Hema/Oncol	Suite 1A	55 Meriden Ave		Southington, CT 06489	
Jere T. W. Licciardello, MD	Hema/Oncol	Suite 1A	55 Meriden Ave		Southington, CT 06489	
Laurie Harrold, MD *	Hema/Oncol	Suite 1A	55 Meriden Ave		Southington, CT 06489	
Deborah A. Sculco, MD *	Hema/Oncol	Suite 1A	55 Meriden Ave		Southington, CT 06489	
Francine Foss, MD	Boston Med Cntr	Med Oncol Section	Evans 556	88 East Newton St	Boston, MA 02118	
Carol Rosenberg, MD	Boston Med Cntr	Med Oncol Section	Evans 556	88 East Newton St	Boston, MA 02118	
Marshal T. Schreeder, MD	Comprehensive Cancer Care Institute	Suite 200	201 Sivley Road		Huntsville, AL 35801	
Richard J. Guallieri, MD	Comprehensive Cancer Care Institute	Suite 200	201 Sivley Road		Huntsville, AL 35801	
Edgar F. Prasthofer, MD	Comprehensive Cancer Care Institute	Suite 200	201 Sivley Road		Huntsville, AL 35801	
Noel C. Estopinal, MD	Comprehensive Cancer Care Institute	Suite 200	201 Sivley Road		Huntsville, AL 35801	
Joseph F. Schneider, MD	Comprehensive Cancer Care Institute	Suite 200	201 Sivley Road		Huntsville, AL 35801	
David Schilling, MD	Univ of Tennessee - Memphis	Div of Hematology & Oncology	3rd Floor - Health Science Cntr	3 North Durlap	Memphis, TN 38163	
Brent Mullins, MD	Univ of Tennessee - Memphis	Div of Hematology & Oncology	3rd Floor - Health Science Cntr	3 North Durlap	Memphis, TN 38163	

*Indicates no sponsor payments identified by corporate accounting records.

9/27/99

67

Trial 1033IL/0030 Sub-Investigators ~ No Response to Request for Disclosure as of the Date of this Report*

Name	address	address	address	address	city.state.zip	Co
Randall P. Rago, MD	Univ of Tennessee - Memphis	Div of Hematology & Oncology	3rd Floor - Health Science Cntr	3 North Dunlap	Memphis, TN 38163	
Pat Adams-Graves, MD	Univ of Tennessee - Memphis	Div of Hematology & Oncology	3rd Floor - Health Science Cntr	3 North Dunlap	Memphis, TN 38163	
Timothy J. Woodlock, MD	St Marys Hosp	89 Genesee St			Rochester, NY 14611	
Robin Lifton, MD	St Marys Hosp	89 Genesee St			Rochester, NY 14611	
Stephen M. Ignaczak, MD *	St Marys Hosp	89 Genesee St			Rochester, NY 14611	
Elizabeth M. Cryan, MD *	St Marys Hosp	89 Genesee St			Rochester, NY 14611	
David W. Lyter, MD	Illinois Masonic Cancer Cntr	901 West Wellington Ave			Chicago, IL 60657	
Mala Vohra, MD	Illinois Masonic Cancer Cntr	901 West Wellington Ave			Chicago, IL 60657	
Angel G. Galvez, MD	Illinois Masonic Cancer Cntr	901 West Wellington Ave			Chicago, IL 60657	
Ira J. Piel, MD	Illinois Masonic Cancer Cntr	901 West Wellington Ave			Chicago, IL 60657	
Yosef H. Plich, MD *	Illinois Masonic Cancer Cntr	901 West Wellington Ave			Chicago, IL 60657	
Marlo Kuperminc, MD	Hematology & Oncology Assoc of VA	Suite 100	1807 Libbie Ave		Richmond, VA 23226	
Frank Call II, MD	Hematology & Oncology Assoc of VA	Suite 100	1807 Libbie Ave		Richmond, VA 23226	
M. Kelly Hagan, MD	Hematology & Oncology Assoc of VA	Suite 100	1807 Libbie Ave		Richmond, VA 23226	
Lawrence Lewkow, MD	Hematology & Oncology Assoc of VA	Suite 100	1807 Libbie Ave		Richmond, VA 23226	
Maurice Schwarz, MD	Hematology & Oncology Assoc of VA	Suite 100	1807 Libbie Ave		Richmond, VA 23226	

*Indicates no sponsor payments identified by corporate accounting records.

9/27/99

88

Trial 1033IL/0030 Sub-Investigators ~ No Response to Request for Disclosure as of the Date of this Report*

Name	address	address	address	address	city.state.zip	Co
H. St. George Tucker III, MD	Hematology & Oncology Assoc of VA	Suite 100	1807 Libbie Ave		Richmond, VA 23226	
Joseph P. Evers, MD	Hematology & Oncology Assoc of VA	Suite 100	1807 Libbie Ave		Richmond, VA 23226	
Paola Rode, MD *	Beth Israel Deaconess Med Cntr	TCC 913C	330 Brookline Ave		Boston, MA 02215	
Mary Anne Fenton, MD *	Beth Israel Deaconess Med Cntr	TCC 913C	330 Brookline Ave		Boston, MA 02215	
Lowell Schnipper, MD	Beth Israel Deaconess Med Cntr	TCC 913C	330 Brookline Ave		Boston, MA 02215	
Robin Joyce, MD *	Beth Israel Deaconess Med Cntr	TCC 913C	330 Brookline Ave		Boston, MA 02215	
Virginia F. Borges, MD	Beth Israel Deaconess Med Cntr	TCC 913C	330 Brookline Ave		Boston, MA 02215	
Thomas E. Boyd, MD	Valley Cancer Group	Intrnl Med Assoc of Yakima, Inc	316 Holton Ave		Yakima, WA 98902	
Jenny Devitt, MD	Valley Cancer Group	Intrnl Med Assoc of Yakima, Inc	316 Holton Ave		Yakima, WA 98902	
Tony Ha, MD	Valley Cancer Group	Intrnl Med Assoc of Yakima, Inc	316 Holton Ave		Yakima, WA 98902	
Sean F. Cleary, Ph.D, MD	Valley Cancer Group	Intrnl Med Assoc of Yakima, Inc	316 Holton Ave		Yakima, WA 98902	
Phillip L. Brooks, MD	Eastern Maine Med Cntr	Cancer Care of Maine	Suite 20	417 State St	Bangor, ME 04401-6674	
Thomas Openshaw, MD	Eastern Maine Med Cntr	Cancer Care of Maine	Suite 20	417 State St	Bangor, ME 04401-6674	
Harvey M. Segal, MD	Eastern Maine Med Cntr	Cancer Care of Maine	Suite 20	417 State St	Bangor, ME 04401-6674	
A. Merrill Garrett, MD	Eastern Maine Med Cntr	Cancer Care of Maine	Suite 20	417 State St	Bangor, ME 04401-6674	
Curtis J. Pink, MD	The Oncology Clinic, P.C.		Suite 303	525 North Foote	Colorado Springs, CO 80909	

*Indicates no sponsor payments identified by corporate accounting records.

9/27/99

§

Trial 033IL/0030 Sub-Investigators ~ No Response to Request for Disclosure as of the Date of this Report*

Name	address	address	address	address	city.state.zip	Co
Daniel T. Tell, DO	The Oncology Clinic, P.C.	Suite 303	525 North Foote		Colorado Springs, CO 80909	
Alan Astrow, MD	St Vincents Hosp	Med Cntr of New York	NR 1411	153 West 11th St	New York, NY 10011	
John Cho, MD	St Vincents Hosp	Med Cntr of New York	NR 1411	153 West 11th St	New York, NY 10011	
Marilyn McLaughlin, MD	St Vincents Hosp	Med Cntr of New York	NR 1411	153 West 11th St	New York, NY 10011	
Teresa Rafferty, RN	St Vincents Hosp	Med Cntr of New York	NR 1411	153 West 11th St	New York, NY 10011	
Vincent Salerno, MD	St Vincents Hosp	Med Cntr of New York	NR 1411	153 West 11th St	New York, NY 10011	
Zulfaqqar Jaffar, MD	St Vincents Hosp	Med Cntr of New York	NR 1411	153 West 11th St	New York, NY 10011	
Ira Halperin, MD	St Vincents Hosp	Med Cntr of New York	NR 1411	153 West 11th St	New York, NY 10011	
Ronald Blum, MD	St Vincents Hosp	Med Cntr of New York	NR 1411	153 West 11th St	New York, NY 10011	
Brenda Cooper, MD	Univ Hosps of Cleveland	Ireland Cancer Cntr	11100 Euclid Ave		Cleveland, OH 44106-5055	
Gary Schnur, MD	Univ Hosps of Cleveland	Ireland Cancer Cntr	11100 Euclid Ave		Cleveland, OH 44106-5055	
Todd D. Shuster, MD	Lahey Clinic	Dept of Med Oncol	41 Mall Road		Burlington, MA 01805	
Joyce McCaffrey, MD	Lahey Clinic	Dept of Med Oncol	41 Mall Road		Burlington, MA 01805	
John H. Wolff, MD	Lahey Clinic	Dept of Med Oncol	41 Mall Road		Burlington, MA 01805	
Daniel Morganstem, MD	Lahey Clinic	Dept of Med Oncol	41 Mall Road		Burlington, MA 01805	
Richard Oberfield, MD *	Lahey Clinic	Dept of Med Oncol	41 Mall Road		Burlington, MA 01805	

*Indicates no sponsor payments identified by corporate accounting records.

9/27/99

70